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The role of SMARCAD1 during replication stress 
Sarah Joseph 
 
 Heterozygous mutations in BRCA1 or BRCA2 predispose carriers to an 
increased risk for breast or ovarian cancer. Both BRCA1 and BRCA2 (BRCA1/2) play 
an integral role in promoting genomic stability through their respective actions during 
homologous recombination (HR) mediated repair and stalled replication fork protection 
from nucleolytic degradation. SMARCAD1 (SD1) is a SWI/SNF chromatin remodeler 
that has been implicated in promoting long-range end resection and contributes to HR. 
Using human cell lines, we show that SMARCAD1 promotes nucleolytic degradation in 
BRCA1/2-deficient cells dependent on its chromatin remodeling activity. Moreover, 
SMARCAD1 prevents DNA break formation and promotes fork restart at stalled 
replication forks. These studies identify a new role for SMARCAD1 at the replication 
fork. In addition to the work presented here, I discuss a method for introducing stop 
codons (nonsense mutations) into genes using CRISPR-mediated base editing, called 
iSTOP, and provide an online resource for accessing the sequence of iSTOP sgRNASs 
(sgSTOPs) for five base editor variants (VQR-BE3, EQR-BE3, VRER-BE3, SaBE3, and 
SaKKH-BE3) in humans and over 3 million targetable gene coordinates for eight 
eukaryotic species. Ultimately, with improvements to CRISPR base editors this method 
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Chapter 1: Introduction 
Portions of this chapter are adapted from:  
Joseph SA, et al. Replication fork remodeling, genome stability and human disease:  
the role of SNF2-family DNA translocases. In submission. 
This chapter was written with help from Angelo Taglialatela, Giuseppe Leuzzi, Raquel 
Cuella-Martin, Jen-Wei Huang, and Alberto Ciccia. 
 
1.1 DNA replication and the replication stress response 
1.1.1 Cell division and the replication machinery 
DNA replication ensures the accurate duplication of the genome during cellular 
proliferation. Failure to accurately duplicate the genome during DNA replication causes 
genomic instability, an enabling characteristic for cancer development [1-3]. In order to 
replicate the genome, a subset of replication initiation sites is licensed in early G1 upon 
assembly of the pre-replication complex (pre-RC), which is composed of the origin 
recognition complex (ORC1-6), CDT1, CDC6 and the replicative helicase, MCM2-7, in a 
head-to-head configuration [4-6]. A subset of MCM2-7 complexes loaded at replication 
initiation sites become activated in S-phase following the binding of CDC45 and the 
GINS complex mediated by the DDK and CDK kinases, resulting in the formation of the 
CDC45-MCM-GINS (CMG) complex, which catalyzes the 3’-5’ unwinding of parental 
DNA strands [7-11]. Unwinding of the parental strands leads to the formation of single-
stranded DNA (ssDNA), which is rapidly coated with the ssDNA-binding RPA trimeric 




then initiated by the DNA polymerase α-primase complex and is then continued through 
the coordinated actions of DNA polymerase ε on the leading strand and DNA 
polymerase δ on the lagging strand [16, 17]. Due to the antiparallel nature of the DNA 
strands, the leading strand is synthesized continuously, while the lagging strand is 
generated discontinuously through the synthesis of Okazaki fragments [18, 19]. 
Replicative DNA polymerases associate with the proliferating cell nuclear antigen 
(PCNA), which facilitates DNA synthesis by increasing the processivity of DNA 
polymerases [20, 21]. Sites of DNA synthesis, also referred to as replication forks, 
progress bidirectionally from an initiation site and terminate as the result of the 
convergence of replication forks moving in opposite directions.  
1.1.2 Extrinsic and intrinsic obstacles to fork progression  
Replication fork progression is frequently challenged by obstacles leading to 
replication stress and genomic instability [22]. Replication obstacles can occur naturally 
or be induced by exogenous agents. Endogenous obstacles include DNA abasic sites, 
modified DNA bases (e.g., oxidized or methylated bases, DNA crosslinks), DNA breaks, 
protein-DNA adducts, unusual DNA structures (e.g., hairpins, triplexes, G-quadruplexes, 
and trinucleotide repeats), replication slow zones (regions AT-rich or poor of replication 
initiation sites), unbalanced nucleotide pools, and collisions with transcription or non-
histone DNA-bound proteins (e.g., cohesin, centromeric proteins, and pre-RCs) [23-25]. 
Replication impediments can also be caused by DNA lesions induced by exogenous 
sources. The most common exogenous sources of replication stress are ultraviolet 
radiation (UV), ionizing radiation (IR) and chemical compounds, such as DNA 




methanesulfonate), topoisomerase inhibitors (e.g., camptothecin) and inhibitors of 
nucleotide synthesis and DNA polymerase activity (e.g., aphidicolin, hydroxyurea) [26]. 
These lesions can stall replication fork progression on two levels: (1) by preventing DNA 
polymerase or helicase movement or (2) causing the replication fork machinery to “run-
off” the strand generating a one-ended DNA double-strand break and replication fork 
collapse [27].  
1.1.3 The replication stress response 
While replication obstacles on the lagging strand are bypassed by the synthesis 
of a new Okazaki fragment, impediments on the leading strand may result in the arrest 
of replication fork progression (Figure 1.1, step I) [28-30]. Small DNA lesions, such as 
abasic sites, UV lesions, small DNA hairpins, that block the leading strand polymerase 
are thought to lead to the formation of RPA-coated ssDNA regions possibly resulting 
from the uncoupling of the CMG helicase and the replicative polymerases [30-35]. More 
recent studies have now shown that bulky barriers that prevent the unwinding of the 
parental DNA strands by CMG also lead to the formation of ssDNA, suggesting fork 
processing by DNA helicases or translocases [36-38]. Formation of RPA-coated ssDNA 
results in the recruitment of the ATR (ataxia-telangiectasia and Rad3 related) kinase 
through its interacting partner ATRIP (ATR-interacting protein) [39-41]. ATR is part of 
the phosphoinositide-3-like kinase kinase (PIKK) family including ATM (ataxia-
telangiectasia mutated), DNA-PKcs (DNA-dependent protein kinase), mTOR 
(mammalian target of rapamycin), and SMG1 which, excluding mTOR, phosphorylate 
serine or threonine residues followed by a glutamine residue (S/TQ) on their target 




(Topoisomerase 2-binding protein 1) in complex with RAD9-RAD1-HUS1 (9-1-1) [43-
47]. ATR phosphorylates the CHK1 kinase and a wide number of DNA replication and 
repair factors to suppress global origin firing, initiate local dormant origin firing, slow 
replication fork movement,  arrest cell cycle progression, and promote replication fork 
stability[48-50]. ATR signaling is also required to initiate the restart of stalled replication 
forks by replication-coupled repair (RCR), which induces the processing of DNA lesions 
in coordination with the replisome to enable the restart of DNA synthesis once the 
obstacles have been bypassed or removed [51].  
1.2 Maintenance of replication fork integrity 
In order to ensure RCR can occur, several pathways have evolved to maintain 
the integrity of the replication fork upon replication stress. These pathways act at three 
levels: (1) allowing the immediate bypass of the damage, (2) pausing and eventually 
resuming progression once the obstacle is cleared, or (3) cleaving and repairing the fork 
(Figure 1.1)[52-54]. How cells determine which pathway to take is in part dependent 
upon PCNA post-translational modification (PTM), the type of lesion stalling the 
replication fork, and cell cycle regulation [54, 55]. 
1.2.1 Fork stalling 
Fork traverse and repriming 
Large DNA-protein crosslinks (DPCs) block DNA synthesis by dramatically 
slowing helicase movement past the lesion [56, 57]. Exogenous agents such as UV and 
chemotherapeutics (cisplatin) or endogenous sources, like formaldehyde, generate 




DPCs and allow bypass. Unlike proteasomal degradation of DPCs, SPRTN does not 
require poly-ubiquitination to degrade its targets [61]. Therefore, SPRTN activity is 
highly regulated to avoid nonspecific proteolysis of the replisome components. As such, 
SPRTN is initially mono-ubiquitinated to prevent recruitment to chromatin due to the 
interaction between the attached ubiquitin and SPRTN’s ubiquitin binding domain (UBZ) 
[62]. It is still unclear which de-ubiquitnating enzyme is responsible for removing the 
PTM, but SPRTN is able to access chromatin only when non-ubiquitinated [62]. 
Furthermore, SPRTN binding to ssDNA activates SPRTN’s protease activity enabling 
DPC degradation [62, 63]. On the other hand, SPRTN’s binding to dsDNA activates its 
autocatalytic activity to negatively regulate itself [62]. Notably, SPRTN’s activity also 
depends on nucleotide synthesis, suggesting that SPRTN can be activated on either the 
leading or lagging strand of the replication fork [61].Finally, SPRTN is cell cycle 
regulated with its expression peaking in S-phase [62, 64, 65]. 
Another factor involved with the removal of DPCs is the helicase RTEL1 
(regulator of telomere length 1). RTEL1 maintains telomere integrity by unwinding T-
loops and G-quadruplex DNA at the telomeres [66]. Recently, RTEL1 has been 
identified as an accessory protein that allows the CMG helicase to bypass undegraded 
DPCs on the leading strand [57]. RTEL1 facilitates CMG bypass of DPCs by unwinding 
the DNA beyond the lesion, generating ssDNA beyond the adduct [57]. Furthermore, 
RTEL1 is required for efficient DPC proteolysis by SPRTN since the absence of RTEL1 
reduced the chromatin binding of SPRTN. On the other hand, for lagging strand DPCs, 




helicase into a steric exclusion mode, in which the lagging strand is excluded from the 
interior of the helicase, enabling the bypass of the legion [67-69]. 
Similarly to DPCs, interstrand crosslinks (ICLs), the covalent linkage between 
nucleotides on opposing strands, generated exogenously by chemotherapeutic agents 
like cisplatin or mitomycin C or endogenously by aldehydes and lipid peroxidation 
prevents DNA helix unwinding and replication progression  [70-72]. In this case, the 
CMG helicases can also bypass ICLs by relying upon the coordinated actions of the 
BLM, RMI1, FANCD2, FANCM, and FANCM’s interacting partners MHF1, MHF2, and 
PCNA [73-76]. FANCM is a translocase that can move along the DNA duplex without 
DNA unwinding [77]. The MHF1 and MHF2 (MHF1/2) heterodimer enhances FANCM 
DNA binding activity crucial for FANCM traverse through an ICL while the interaction of 
FNACM with PCNA through its PCNA-interacting protein (PIP) box also promotes ICL 
traverse [74, 77]. However, how the interaction between FANCM and PCNA promotes 
traversal is still unknown [74]. Additionally, FANCM requires the helicase activity of BLM 
together with the RMI2 for proper ATR-dependent recruitment to stalled replication forks 
and efficient ICL traverse [75]. Notably, the association of FANCM with the CMG 
helicase requires FANCD2 and loss of FANCD2 reduces ICL bypass [76]. Subsequently 
when two converging forks are stalled by an ICL, TRAIP-dependent ubiquitination of the 
CMG helicase controls whether the ICL is repaired by the Fanconi Anemia pathway [78] 
or by direct unhooking by NEIL3 [79, 80]. Ultimately, after a lesion is skipped, primase 
activity to generate a free 3’-hydroxyl is required for DNA synthesis to resume by the 




PRIMPOL is the mammalian DNA polymerase-primase that has been identified 
to re-prime the leading strand after a lesion at a stalled replication fork (Figure 1.1, step 
III) [81-83]. PRIMPOL is an error-prone member of the Archeo-Eukaryotic family of 
primases containing a DNA polymerase domain and a DNA primase domain [84]. 
Because unchecked primase activity can be mutagenic [84, 85], PRIMPOL activity is 
inherently regulated by its weak affinity for DNA [86]. Consequently, PRIMPOL requires 
RPA to be recruited to stalled forks [84, 87]. Additionally, RPA stimulates the primase 
function of PRIMPOL while PolDIP2 (polymerase δ-interacting protein 2) positively 
regulates PRIMPOL’s primer extension activity [84, 86, 87]. Notably, PRIMPOL 
reprimes DNA substrates containing G-quadruplexes and chain terminating nucleosides 
[88, 89]. While the primary role of PRIMPOL is repriming after a lesion, PRIMPOL also 
plays a minor role in incorporating DNA nucleotides opposite the lesion, known as 
translesion synthesis (TLS) [81]. 
Translesion Synthesis 
PRIMPOL plays a minor role in TLS by specifically only bypassing through 8-oxo-
guanine, deoxyuracil, and pyrimidine dimer lesions [81-83, 90]. Unlike, PRIMPOL, the 
major TLS polymerases are recruited to the lesion by PCNA mono-ubiquitination at 
lysine 164 (K164) by the ubiquitin-conjugating enzyme (E2) RAD6 and the ubiquitin 
ligase (E3) RAD18 [91-94]. RAD18 is recruited in the presence of ssDNA and has a 
preference for forked DNA by its SAP (SAF-A/B, Acinus and PIAS) domain [93-96]. This 
mono-ubiquitination allows the TLS polymerases to out compete polymerase δ for 
access to PCNA and promote subsequent DNA synthesis in response to DNA damage 




DNA polymerases along with Pol ζ from the B-family of polymerases (Figure 1.1, step 
II) [97-103]. The other TLS polymerases include the X-family polymerases, Pol μ and 
Pol λ, and the A-family polymerases, Pol θ and Pol ν that primarily play a role in gap 
filling for other DNA repair pathways such as base excision repair (BER) and non-
homologous end-joining (NHEJ) [104-113]. As opposed to the replicative polymerases, 
TLS polymerases are characterized by low processivity, low efficiency, and low 
accuracy. TLS polymerases have larger active sites that permits Hoogsteen-base 
pairing of nucleotides and accommodates damaged or distorted backbones allowing 
them to incorporate nucleotides opposite a lesion but lack the 3’-5’ exonuclease proof-
reading domain, thus making them error prone [114-117]. Most of the Y-family TLS 
polymerases interact directly with mono-ubiquitinated PCNA through their respective 
ubiquitin binding domains, ubiquitin binding zinc-finger (UBZ) for Pol κ and Pol η and the 
helical ubiquitin binding motif (UBM) for Pol ι, with additional interactions to PCNA with 
non-canonical PCNA interacting motifs [118-120]. REV1, on the other hand, interacts 
with ubiquitin through its UBM with additional contacts with PCNA through its BRCA1 C-
terminus (BRCT) domain and the polymerase assisted domain (PAD) [121, 122]. 
Generally, TLS requires the sequential action of two groups of polymerases to (1) insert 
the nucleotide across from the lesion (Pol κ, Pol η, Pol ι) followed by (2) the extension 
the nascent strand (Pol κ or Pol ζ) (Figure 1.1, step I) [99, 123-128]. REV1 primarily 
acts as a molecular bridge between PCNA and different TLS polymerases to facilitate 
the switching from the high-fidelity replicative helicases but can also insert bases across 




and abasic sites) [129-132]. Finally, once synthesis has passed the lesion the 
replicative polymerases can take over to finish DNA replication [132].  
Recent studies have challenged the idea of mono-ubiquitinated PCNA as the 
mediator for TLS recruitment [91, 133-138]. In yeast, Pol ζ and REV1 were activated 
independently of PCNA ubiquitination when the integrity of the interaction between 
PCNA and Pol δ was impaired [91]. Furthermore, mutations in the yeast and human Pol 
η UBZ domains did not compromise TLS activity through UV-induced damage [134-
137]. In avian DT40 cells, disrupting REV1 induced more fork stalling than the disruption 
of PCNA ubiquitination while PCNA ubiquitination was essential for post-replicative gap 
filling [138]. Moreover, in mouse embryonic fibroblasts (MEFs) about 30% of TLS still 
occurred although PCNA polyubiquitination was disrupted using a PCNA KR mutant 
(Pcnak164R/K164R) [133]. Additionally, Pol η interacts with RAD18 and plays a non-
enzymatic role to promote RAD18-mediated PCNA mono-ubiquitination [139]. Finally, 
REV1 interacts with ubiquitinated RAD18 to promote RAD18 accumulation to PCNA 
and subsequent mono-ubiquitination [140].Taken together, this suggests that mono-
ubiquitination of PCNA may enhance TLS efficiency but is not necessary for TLS 
recruitment while REV1 is the main mediator for TLS at a stalled replication fork.  
The Interplay between Translesion Synthesis and Homology Directed Repair 
Homology directed repair (HDR) is a compensatory pathway to TLS in which 
cells bypass lesions in an error-free manner using a homologous template [141, 142]. 
Initially, it was thought that PCNA K63-linked polyubiquitination by HLTF and SHPRH 
RING ubiquitin ligase domains mediated the switch between TLS and HDR [143-146]. 




unnecessary for efficient HDR [147]. In this study, expression of a PCNA that cannot 
form polyubiquitin chains (K63R) was able to restore the cell cycle defect of the PCNA 
K63R mutants and led to a reduction in translesion synthesis [147]. As such, 
SUMOylation of PCNA at K164 by PIAS4 and PIAS1 has been suggested as an 
alternative mechanism to promote HDR [148]. Consistent with the notion that HDR is 
compensatory to TLS, POLDIP2, an interactor of Pol ζ, Pol η and REV1 suppresses 
HDR and subsequently increases TLS [149]. But the mechanism as to how this occurs 
is still unknown [149].  
Fork reversal and template switching 
Nearly 45 years ago it was proposed that stalled replication forks may undergo 
fork regression to form a structure that will allow error-free bypass through HDR, instead 
of using an error-prone pathway [150]. 27 years later this structure was identified in vivo 
by electron microscopy (EM) in response to genotoxic agents [151, 152]. A regressed or 
reversed fork is formed when the parental strands re-anneal thereby extruding the 
nascent DNA into a “chicken foot” or four-way structure [37, 150, 151, 153-157]. Fork 
reversal has been suggested to prevent ssDNA accumulation, allow more time to repair 
the lesion, re-position the lesion into dsDNA to enable excision repair, or prevent 
synthesis across SSBs which could result in the formation of deleterious DNA double 
strand breaks (DSBs) [37, 151, 158]. Furthermore, this structure has been suggested to 
allow the bypass of the lesion in an error-free manner by allowing the leading strand to 
use the lagging strand as a template for DNA synthesis [150]. While bypass via the 
reversed fork has been demonstrated in vitro there has been no in vivo evidence in 




While replicating cells have a basal level of reversed forks, exposure to genotoxic 
stress increases fork reversal due to ATR signaling [37, 151, 161]. Furthermore, rapidly 
proliferating embryonic stem cells use reversed forks as a way of protecting them from 
endogenous replication stress [162]. Moreover, fork remodeling is a global response 
and can occur even at replication forks that are not directly challenged by DNA lesions 
[161]. Fork reversal is mediated by the SNF2-family fork translocases HLTF, ZRANB3, 
and SMARCAL1 along with the recombinase RAD51 and the helicase FBH1 (Figure 
1.1, step IV) [37, 153, 154, 156, 163-166].  
Surprisingly, RAD51 does not require its strand exchange activity and does not 
have any fork remodeling activity of its own but has still been demonstrated to catalyze 
fork reversal in vivo [160, 164]. Therefore, it has been proposed that RAD51 could act 
like a platform to promote fork reversal [164]. Importantly, the non-enzymatic fork 
regression function of RAD51 depends upon FBH1 suggesting that FBH1 and RAD51 
cooperate to regress forks in vivo [164]. FBH1 is a recruited to replication forks under 
stressed conditions by its PIP box and AlkB homolog 2 PCNA interaction motif (APIM) 
[163, 167, 168]. Notably, FBH1-mediated fork reversal depends on the DNA binding 
activity of RAD51 [164]. RAD51 requires BRCA2 as a mediator facilitating RAD51 
loading [169-173]. However, the fork reversal function of RAD51 does not rely upon 
BRCA2 [155, 174]. While RADX has been demonstrated to counteract RAD51 filament 
assembly on replication forks [175, 176] and RECQ5 has been shown to disrupt RAD51 
nucleoprotein filaments assembled on stalled replication forks to prevent fork reversal 
[177, 178], there are still open questions about what factors mediate RAD51 loading 




Although the SNF2-family of translocases share fork reversal activity, they play 
non-redundant functions during replication stress [154, 179, 180]. Notably, only 
SMARCAL1 protects telomeres from replication stress and is required for proper 
telomere replication [179-185]. At the molecular level these remodelers exhibit 
differences in their respective modes of action. SMARCAL1 associates with the 
replication fork under unstressed conditions, but becomes enriched during replication 
stress through its interaction with RPA [154, 155, 186-192]. FBH1, ZRANB3, and HLTF 
recruitment are PCNA-dependent. ZRANB3 associates to sites of replication stress in a 
PCNA-dependent manner through its PIP box and APIM and contains a NPL4 zinc-
finger (NZF) motif that binds K63-linked polyubiquitinated PCNA which is promoted by 
HLTF and UBC13 [156, 193-196]. Finally, HLTF recruitment has recently been shown to 
be dependent on PCNA K164-ubiquitination [196], but catalyzes the PCNA K63-linked 
polyubiquitination that ZRANB3 partially depends on [143, 197]. Along with the different 
modes of recruitment and activation, the remodelers display distinct substrate 
specificities. SMARCAL1 primarily acts on fork substrates containing leading strand 
gaps. Instead both ZRANB3 and HLTF can reverse forks on leading and lagging strand 
with equal affinity, while HLTF has a strong preference for available 3’-hydroxy groups 
[187, 193, 198-201]. ZRANB3 could be preferentially acting upon forks stalled by 
damaged DNA bases that could be excised through its endonuclease activity [194]. 
These observations raise the possibility that SMARCAL1, ZRANB3 and HLTF might 
operate on distinct types of stalled forks induced in response to replication stress. 
These structures could arise independently from each other on distinct stalled forks or 




conditions where extensive fork remodeling is thought to occur (e.g., BRCA1/2-deficient 
cells). It has been proposed that, under those circumstances, SMARCAL1, ZRANB3, 
and HLTF may act cooperatively on their preferred substrates generated on the same 
fork and that failure at any point in these sequential steps could impair fork reversal 
[154, 202]. SMARCAL1 could, for example, generate fork substrates amenable to 
HLTF-mediated fork remodeling by pulling the leading strand closer to the fork junction, 
and HLTF could control ZRANB3-dependent remodeling by regulating the levels of 
PCNA polyubiquitination. However, these models remain to be proven and the 
dynamics between fork remodelers elucidated.  
Fork reversal is a double-edged sword. While failure to reverse forks leads to 
genomic instability by MUS81-mediated cleavage of persistently stalled forks, excessive 
fork reversal can also lead to DNA damage [175-177, 203-205]. Therefore, fork 
remodelers need tight regulation to prevent unscheduled fork reversal [151, 175, 176, 
203, 205, 206]. Upon DNA binding, SMARCAL1 is negatively regulated by ATR 
phosphorylation on serine 652 (S652) in between the two lobes of its ATPase domain 
[203]. Moreover, RAD52 has recently been demonstrated to prevent SMARCAL1-
mediated fork reversal perhaps by competing for the same RPA-binding site [181, 207-
210]. Additionally, HLTF activity at the fork is restrained by the helicase FANCJ [206]. 
Interestingly, RPA has been demonstrated to impair ZRANB3 fork remodeling activity in 
vitro, although ZRANB3 does not have any clear RPA binding domains, suggesting 
RPA may sterically hinder ZRANB3’s binding to DNA [198]. FBH1 has been 
demonstrated to negatively regulate RAD51 by promoting RAD51 K58/64 ubiquitination 




ssDNA-binding protein, RADX, also suppresses RAD51 activity during replication stress 
by competing with RAD51 for ssDNA binding [175, 176]. In addition to the negative 
regulators of helicase activity, the EXD2 nuclease counteracts fork reversal by 
processing stalled forks into a structure refractory for reversal [213]. Similarly, RECQ1 
plays an important role by counteracting reversed forks once repair/bypass/pausing is 
completed allowing fork restart (Figure 1.1, step V) [205]. Subsequently, poly(ADP-
ribose)-polymerase 1 (PARP1), has been demonstrated to inhibit RECQ1 and acts like 
a master switch to prevent premature fork restart [205]. 
Fork protection 
Fork protection is a second mechanism that restricts genomic instability caused 
by fork reversal. While reversed forks may aid in error-free repair or bypass of a lesion, 
unprotected nascent DNA extruded from the “chicken foot” structure is vulnerable to 
excessive degradation by nucleases [154, 155, 165, 174, 214-220]. The reversed arm 
of the fork is a prime substrate for nuclease degradation by MRE11, WRN/DNA2, and 
EXO1 (Figure 1.1, step IV) [153, 154, 165, 221-223]. The endonuclease CtIP has also 
been demonstrated to have a role in fork resection, however, its role remains 
controversial [165, 218, 224-226]. In order to prevent degradation, the recombinase 
RAD51 forms a nucleoprotein filament on the stalled fork to protect the regressed arm 
and is stabilized by several factors such as Abro1, WRNIP1, FANCA, FANCD2, BOD1L, 
SETD1A, and the RAD51 paralogs (XRCC2 and RAD51C), BRCA1, BRCA2, PALB2, 
and BARD1 (Figure 1.1, step IV) [214-218, 226-229]. Interestingly, BOD1L and 
SETD1A protect cells from DNA2- but not MRE11-mediated resection [218, 228]. But 




Nuclease recruitment to replication forks depends on the actions of multiple 
factors including PTIP, PARP1, MLL3/4, CHD4, and SAMHD1 (Figure 1.1, step IV) 
[174, 220, 225, 230, 231]. Notably, PP1 is a protein phosphatase that interacts with 
RIF1 [232]. This RIF1/PP1 complex dephosphorylates WRN and DNA2 preventing 
activation and over-resection [222, 223]. Recently the MRE11 interacting protein 
(MRNIP) has been identified to prevent MRE11- dependent degradation of the reversed 
arm of the fork by inhibiting MRE11 exonuclease but not endonuclease activity [233, 
234]. Notably, inhibition of MRE11 endonuclease activity by the chemical inhibitor 
PFM03 can prevent fork degradation in BRCA2-deficient cells, suggesting that MRE11 
uses both its endo- and exonuclease activities to process the stalled replication fork 
[233, 235]. Intriguingly, although MRNIP binds to MRE11, inhibition of DNA2-mediated 
degradation in MRNIP-deficient cells suppresses fork degradation, suggesting that 
MRE11 and DNA2 may work together to process stalled forks [233]. On the other hand, 
it is possible that MRNIP-deficiency generates fork structures that require DNA2-
mediated processing [233]. In contrast, the histone methyltransferase, MLL3/4, in 
association with PTIP, the chromatin remodeler CHD4, and PARP1 play a role in 
recruiting MRE11 while SAMHD1 stimulates MRE11 exonuclease activity [174, 220, 
225, 230, 231, 236].  
1.2.2 Fork collapse 
Forks irreversibly arrested by DNA lesions undergo MUS81- / SLX4-dependent 
fork cleavage, which leads to DSB formation and fork collapse (Figure 1.1, step VI) 
[165, 237, 238]. MUS81 and SLX4 cleaves the regressed fork structure generating a 




DSB formation after fork stalling while loss of either MRE11 or EXO1 also prevents DSB 
formation, suggesting that MUS81 cleaves replication forks after nucleolytic processing 
[165]. Additionally, PARP1 prevents fork collapse by stopping premature fork restart by 
RECQ1 [151, 239]. Interestingly MUS81-dependent processing is promoted by the 
histone methyl transferase EZH2 only in BRCA2-deficient cells suggesting different 
roles for BRCA1 and BRCA2-mediated protection [240]. A recent study has suggested 
that WRNIP1 protects replication fork from SLX4 mediated to prevent unnecessary or 
untimely cleavage of the reversed fork structure [216, 238]. Ultimately, fork processing 
by MUS81 and SLX4 leads to pathways that repair collapsed forks. 
Repair of collapsed forks 
After the generation of a DSB either by MUS81-SLX4 processing or replication 
fork run-off into a SSB, collapsed forks are repaired by an HR-mediated pathway 
(Figure 1.1, steps VI-VIII). The HR-mediated fork restart pathway requires the function 
of RAD51 for strand invasion followed by DNA synthesis aided by the MCM8-9 helicase 
in complex with MCM8IP (HROB) (Figure 1.1, steps VII-VIII) [241-244]. Additionally, 
this HR-mediated fork restart pathway relies upon fork convergence and is mediated by 
the E3 SUMO ligase NSMCE2 [245]. Moreover, unrepaired DSBs that persist into late 
G2 and mitosis can be resolved by a RAD52-dependent mutagenic pathway called 
mitotic DNA synthesis (MiDAS) (Figure 1.1, steps VII-VIII) [241, 246]. In this case, 
RAD52 facilitates MiDAS by promoting microhomology mediated strand annealing that 
is followed by extensive DNA synthesis using a modified replisome containing POLD3 
(Figure 1.1, steps VII-VIII)[247, 248]. Notably, a recent study has suggested that in the 




DNA synthesis by RAD52-POLD3 through the recruitment and activation of the RAD18-
SLF1 complex thereby providing a mechanism for the pathway choice between HR-
mediated repair and MiDAS [249]. Interestingly, in yeast a RAD51- and RAD52-
dependent pathway called break induced replication (BIR) proceeds through the 
invasion of the broken end into a homologous template, followed by conservative DNA 
synthesis until the end of the chromosome [250-258]. While BIR has been extensively 
studied in yeast, mammalian BIR and the proteins involved are still poorly understood 
[257-265]. While MiDAS and the repair of DSBs resulting from oncogene-induced 
replication stress, or induced during alternative lengthening of telomeres (ALT), have 
been suggested to be similar to the BIR pathway described in yeast [251, 252, 256, 
266], the molecular mechanisms of BIR-like processes in mammals remain to be fully 
defined. 
1.2.3 The role of chromatin in replication fork maintenance  
Several studies have now highlighted the importance of chromatin and chromatin 
bound proteins during replication stress. A study by Feng and colleagues, recently 
identified that replication fork stalling induces chromatin compaction through the post-
translational modification of the histone H2BK33 by the Clr6 deacetylase in the fission 
yeast Saccharomyces pombe [259]. Additionally, in yeast, failure to generate 
heterochromatin during replication stress leads to the separation of the CMG helicase 
from the replicative polymerases and increased the frequency of fork collapse [259]. 
Similarly, in mammalian cells, replication stress leads to the loss of acetylated histones 
mediated by ubiquitin-independent proteasomal degradation suggesting that chromatin 




chromatin compaction due to loss of histone H1 leads to an increase in stalled forks 
caused by transcription-replication conflicts, while loss of the HMGB1 gene leads to 
faster fork progression [261]. These findings indicate that chromatin conformation is a 
critical regulator for replication fork dynamics [261]. Interestingly, the histone chaperone 
FACT targets the histone variant macroH2A1.2 deposited at sites of replication stress, 
protecting cells from genomic instability and aberrant senescence [262]. Chromatin 
remodeling during replication stress is important for mediating the restart of stalled 
forks. In yeast, chromatin remodeling by the SNF2-family remodelers Chd1 and Isw1 
along with RSC and the chromatin modifiers Gcn5 and Set1 enable extensive resection 
by Exo1 to promote the recruitment of cohesin to stalled replication forks and facilitate 
fork restart [263]. In mammals, cohesin loading protects stalled replication forks from 
extensive nucleolytic degradation and promotes the recruitment of fork protection 
factors: RAD51, BRCA2, and WRNIP1 [219]. On the other hand, improper accumulation 
of cohesin presents an obstacle for replication fork progression and has been 
associated with replication fork slowing, fork collapse, and DSB accumulation [219, 
264]. Furthermore, SETD1A protects replication forks by promoting histone H3 lysine 4 
(H3K4) methylation which enhances the chaperone activity of FANCD2 to prevent 
degradation suggesting that both histone modification and mobility are important for 
replication fork protection [228]. Additionally, disrupting global nucleosome deposition 
by depleting CAF-1 leads to DNA2-mediated fork degradation [196]. Taken together, 
these studies underscore the importance of replication stress induced chromatin 




1.2.4 The role of SNF2-family remodelers at the fork 
The SNF2 family of proteins is structurally characterized by a SWI/SNF2 
(switch/sucrose non-fermenting) helicase domain with a bi-lobed RecA-type ATPase 
configuration, which is present in the yeast protein Snf2 [265]. Functionally, SNF2-family 
members have been primarily involved in chromatin remodeling. The SNF2 family 
includes SNF2-like, INO80, RAD54-like, SSO1653-like, RAD5/16-like, and SMARCAL1-
like subfamilies [265, 266]. In addition to the previously described fork reversal factors, 
other members of the SNF2- family have been involved at different stages of the 
replication stress response. So far, mammalian INO80, ATRX, CHD4 (Mi-2β), CHD1L 
(ALC1), SMARCA4 (BRG1), SMARCA2 (BRM), SMARCA5, SMARCAD1, ERCC6L 
(PICH) and BTAF1 (MOT1) have been described to be recruited to or act at stalled 
replication forks. 
The SNF2-like group: SMARCA- and CHD-family members 
The SNF2-like group of remodelers contain the SNF2-like helicase domain along 
with domains that recognize histone tail post-translational modifications (Figure 1.2) 
[265, 266]. The CHD-type remodelers typically contain tandem chromodomain enabling 
them to bind to methylated histones [267]. CHD1L (ALC1) is often included in the CHD-
type remodelers despite lacking an identifiable chromodomain and instead containing a 
macrodomain that binds to PAR-moieties [268, 269]. So far only CHD1L and CHD4 
have been attributed roles at the replication fork [225, 270]. SMARCA-type remodelers 
contain a bromodomain to bind to acetylated histone tails (Figure 1.2) [271]. Of these, 
so far SMARCA4 (BRG1) and SMARCA2 (BRM) have been demonstrated to be 




functional features, the role of CHD- and SMARCA- type factors in replication stress 
responses implicates histone modification and chromatin remodeling. Loss of either 
SMARCA4 or SMARCA2 leads to slower replication fork dynamics and a decrease in 
inter-origin distance suggesting an increase in origin firing in response to the slower 
replication fork progression of unperturbed replication forks [272]. Additionally, 
SMARCA4 colocalizes with ORC1 and PCNA and has been shown to interact with 
TOPBP1, BRCA1, and CHD4 [272-274]. CHD4 can bind methylated histones as well as 
PAR-moieties and is recruited to IR-induced DSBs in a PARP-dependent manner [275]. 
CHD4 was demonstrated to promote nucleolytic degradation in BRCA2-mutant through 
the control of MRE11 recruitment [225]. Mechanistically, CHD4 may promote chromatin 
decondensation at sites of replication stress facilitating MRE11 accessibility to DNA 
[276]. On the other hand, it has been demonstrated that the chromatin decondensation 
induced by the chemotherapeutic agent camptothecin is dependent on CHD1L function 
[270]. Loss of CHD1L led to slower replication fork speed during replication stress [270]. 
Since CHD1L is recruited for nucleotide excision repair and IR-induced damage repair 
dependent on PARP1, it is possible that PARP1 may also recruit CHD1L to sites of 
replication stress [269, 270, 277].  
SMARCA1 and SMARCA5 form the ISWI group of chromatin remodelers and 
contain HAND, SANT, and SLIDE domains which regulate the specificity of the helicase 
domain [278] (Figure 1.2). The ISWI family of remodelers associate with several 
accessory proteins in different complexes to mediate the remodeling of chromatin such 
as the WICH, NoRC, RSF, CHRAC, NURF, CERF, and ACF complexes [279]. Both 




SMARCA5 has been functionally implicated [191, 280]. In particular, SMARCA5 
associates with BAZ1B (in the WICH-complex) and PCNA to maintain euchromatin 
during replication [280]. This suggests that nucleosome remodeling is a crucial for 
proper replication dynamics and response to replication stress agents. 
Unlike the other SNF2 chromatin remodeling sub-families, INO80-type 
remodelers do not have a specific nucleosome binding motif and their ATPase region 
contains a large insertion (Figure 1.2) [281]. Ino80, the founding member of this sub-
family [282-287]. In yeast, the INO80 complex, in which Ino80 is the catalytic subunit 
stabilizes stalled replication forks, by a still unknown mechanism [288]. In humans, the 
INO80 complex is recruited to replication forks by BAP1’s binding to ubiquitinated H2A 
during unperturbed DNA synthesis [289]. Furthermore, BAP1 promotes replication fork 
restart through INO80 and RAD51 recruitment [290]. 
The SSO1653- and RAD54-like factors involved at the replication fork 
ATRX is a RAD54-like factor that forms a histone chaperone complex with DAXX 
to promote H3.3-mediated heterochromatinization at loci including centromeres, 
telomeres, CpG-islands, imprinted regions, and endogenous retroviral elements [291-
293]. ATRX has been suggested to protect replication forks from MRE11-dependent 
degradation through MRE11 sequestering, similarly to its role at telomeres [294, 295]. 
How ATRX sequesters MRE11 and whether ATRX function is limited to 
heterochromatin sites still needs to be elucidated. On the other hand, RAD54 can 
regress and restore stalled replication forks in vitro with a preference towards fork 




branch migration functions of RAD54 as well as promote in vitro fork regression by 
RAD54 over fork restoration [160, 296, 297]. 
Finally, a brief mention to ERCC6L (PICH) and BTAF1 (MOT1) from the 
SSO1653 family of helicases (Figure 1.2), notable for their preference for non-
chromatin substrates [265]. ERCC6L is a translocase that is recruited to kinetochores to 
monitor tension and facilitate the resolution of sister chromatids during anaphase [298, 
299]. ERCC6L activity is critical for the resolution of ultrafine bridges generated by 
unresolved recombination intermediates, and sister chromatid bridging due to under-
replication or unprotected replication forks [300-302]. Therefore, loss of ERCC6L leads 
to chromosomal aberrations, micronuclei, and cell death [302]. Although BTAF1 has 
been previously described in the context of transcription regulation [303, 304], it was 
also identified by Isolation of Proteins on Nascent DNA (iPOND) to be enriched at 
collapsed replication forks [191]. Interestingly, a PIP box has been found in the BTAF1 
protein and loss of BTAF1 described synthetic lethal with the RPA interacting factor 
ETAA1 [191, 305]. Considering the role of ETAA1 in maintaining replication fidelity by 
facilitating proper chromosome alignment and spindle assembly checkpoint it remains 
possible that BTAF1 functionally resembles ERCC6L [46, 305]. Alternatively, BTAF1 
may be enriched at collapsed forks because of transcription-replication collisions.  
Overall, several chromatin remodeling factors are recruited to stalled replication 
forks, but their respective mechanism of actions need to be determined. These studies 
underscore the importance of chromatin remodeling to replication fork progression and 




contexts around stalled replication forks to gain new insights into replication stress-
induced dynamics. 
1.2.5 Methodologies to study replication fork transactions 
The current gold-standard assay used to study replication fork dynamics in 
response to replication stress relies on DNA fiber and combing techniques (Figure 1.3) 
[306-313]. These techniques utilize thymidine analogs to label the progression of the 
fork, followed by the stretching of the DNA onto a glass coverslip to obtain DNA fibers 
with a resolution limit of 1 μm, corresponding to 2-4 kb [307, 312-314]. In addition to 
having resolution constraints that do not enable visualization of fork structures, DNA 
fiber/combing techniques are unable to discriminate between leading and lagging 
strand-dependent DNA synthesis. Unlike DNA fiber techniques, EM enables the 
visualization and quantification of replication fork structures with a higher resolution 
around ~30-50 base pairs, thereby permitting the discrimination of ssDNA gaps and 
reversed forks [37, 157, 315-317]. Despite its high resolution, EM only provides a 
snapshot of replication intermediates captured at a single time point. Interestingly, EM 
studies have shown that regressed forks contain nucleosomes, indicating that chromatin 
remodeling may play an important role in fork remodeling [318]. However, EM-based 
approaches, and also DNA fiber/combing techniques, lack the ability to discern the 
influence of different chromatin contexts on replication fork metabolism and visualize 
proteins associated with distinct replication fork intermediates. Current approaches to 
detect proteins associated with replication forks rely primarily on the iPOND technology, 
which enables to pull down and identify proteins bound to nascent DNA by western 




identifying fork-associated proteins, iPOND technologies do not provide spatial 
information on the location of the identified factors. Recent studies led to the 
development of proximity ligation assay (PLA)-based approaches that enable the 
detection of proteins on nascent DNA by standard microscopy in response to replication 
stress [154, 319]. To improve the resolution of PLA-based applications, these methods 
could be coupled with super-resolution imaging technologies, which have been shown 
to enable the mapping of chromatin-associated proteins and chromatin context around a 
replicating area [239, 320]. Future developments of super-resolution imaging may also 
allow the direct visualization of reversed forks and other replication fork transactions, 
thus enabling the study of replication fork dynamics through live imaging-based 
analyses. These techniques could be coupled to biochemical assays that employ 
Xenopus egg extracts [321-324] or purified replication factors [28, 325, 326] to study 
replication fork progression with and without fork barriers. Alternative biochemical 
assays could utilize recombinant proteins to monitor enzymatic reactions on fork-like 
substrates [166, 187, 193] and define DNA transactions using single-molecule 
technologies, such as DNA curtains [327-329] or optical tweezers (Figure 1.3) [69, 330, 
331]. Such approaches would contribute to determine the influence of DNA repair 
factors on replication fork transactions.  
Standard DNA fiber/combing assays can discern global changes in fork 
progression but lack the ability to detect alterations caused by specific genomic 
contexts. To overcome this limitation, DNA combing techniques have been combined 
with fluorescence in situ hybridization to monitor replication fork progression at single 




334]. SMARD allows the study of a limited number of genomic loci at a time. More 
recently, the use of optical mapping technologies have enabled the mapping of 
fluorescently-labeled replication tracts to genomic sites in human cells and Xenopus 
extracts [335, 336]. In addition, nanopore sequencing-based approaches, such as D-
NAscent or FORK-seq, have been shown to discriminate thymidine analogue 
incorporation and map DNA replication sites in yeast and mouse pluripotent stem cells 
[337-339]. We expect that further developments of optical mapping and nanopore 
sequencing technologies will enable genome-wide detection of site-specific replication 
events under normal or replication stress conditions in human cells.  
Classical DNA fiber/combing assays are also unable to specifically analyze 
replication forks that have encountered DNA lesions, since not detectable, thus 
rendering difficult the study of DNA lesion bypass or repair events. Recent studies have 
utilized digoxigenin-labeled psoralen to visualize DNA crosslinks on DNA fibers and 
study the bypass of those lesions (Figure 1.3) [73]. Similar approaches might be 
possible using antibodies that detect other DNA lesions (e.g., anti-cisplatin modified 
DNA antibody). Alternative methods employing the E.coli Tus-Ter system have been 
employed in yeast and mammalian cells to study the repair of a single, site-specific 
replication barrier [340, 341]. More recently, a nuclease-dead Cas9 has been 
demonstrated to be a programmable barrier for replication fork progression [342]. 
Combining site-specific fork barriers with PLA and next-generation sequencing may 
enable the discrimination of proteins recruited to a single stalled fork and the detection 




techniques to study replication dynamics will provide important insights into the 
mechanisms that control replication fork reversal and other fork transactions. 
1.2.6 Genomic consequences 
Failure to resolve replication stress can lead to fork collapse, under-replication, 
and mutagenesis which can contribute to DNA aberrations, DNA damage, and human 
disease (Figure 1.4). Dysregulation of ATR signaling contributes to DNA breaks and 
cellular senescence [343, 344]. As such, inhibition of ATR leads to increased ssDNA 
and RPA accumulation due to increased origin firing by CDK2 [343]. When this occurs, 
ssDNA exceeds the accumulation of RPA at the fork leading to  fork cleavage by 
nucleases [343]. Cells that do manage to progress through S-phase, arrested at G2-M 
leading to cellular senescence [343]. On the other hand, persistent ATR signaling, in the 
absence of DNA damage, leads to persistent CHK1-depedent cell cycle arrest and p53-
dependent senescence [344].  
While TLS is potentially mutagenic, issues with TLS leads to decreased cellular 
survival and replication fork blockage [141, 345-347]. Dysregulation of the TLS 
polymerases is often associated with unresolved replication stress leading to lingering 
DNA damage in G1-cells marked by 53BP1, called 53BP1 nuclear bodies, and 
increased micronuclei formation (Figure 1.4) [348]. Furthermore, loss of PCNA mono-
ubiquitination is associated with aberrant TLS recruitment in undamaged conditions 
leading to an overall increase in mutagenesis [349]. Moreover, overexpression of 
SHPRH or loss of HLTF also increases genomic mutations due to aberrant TLS [146]. 
However, loss of TLS function is also associated with increased mutagenesis [350]. 




used appropriately. Besides SPRTN’s role in DPC removal, SPRTN is also an important 
regulator for TLS activity [351-353]. Therefore, loss of SPRTN has been demonstrated 
to lead to an increase in mutagenesis, chromosomal aberrations, cellular senescence, 
increased sister chromatid exchanges, and sensitization to DNA damaging agents [62, 
351-355]. 
As mentioned before, extensive DNA degradation of the reversed arm of the fork 
leads to chromosomal aberrations and cell death due to replication fork collapse by 
MUS81 (Figure 1.4) [153, 155, 165, 174]. Therefore, loss of the replication fork 
protectors or unrestrained replication fork reversal increases DNA damage 
accumulation and chromosomal abnormalities [154, 175, 176, 213-216, 226, 227]. 
Notably, loss of SAMHD1, a factor that promotes MRE11 exonuclease-mediated 
resection at stalled forks, leads to the accumulation of cytosolic ssDNA generated by 
RECQ1-mediated DNA displacement and MRE11 endonuclease-dependent flap 
cleavage [230]. Cytosolic DNA is sensed by the DNA the cGAS-STING pathway 
triggering the expression of interferon-stimulated genes and the activation of the 
inflammatory response [356-358]. Furthermore, the accumulation of cytosolic DNA 
depends on MUS81 activity [359]. Taken together, this could suggest that extensive 
replication fork degradation and fork collapse can lead to an aberrant inflammatory 
response (Figure 1.4). Overall, the replication stress response needs to be finely tuned 
in order to prevent genomic instability contributing to human disease. 
Failure to continue replication during S-phase leads to under-replication and 
chromosomal breakage (Figure 1.4) [360, 361]. As such, difficult to replicate regions, 




chromatid bridging [361]. Failure to resolve these bridges leads to cell cycle arrest, mis-
segregation, and cell death (Figure 1.4) [301, 360-362]. Furthermore, common fragile 
sites are associated with hypoacetylated histones and chromatin compaction [363]. 
Increasing histone acetylation in these areas leads to a decrease in chromosome 
breakage, suggesting that these areas are susceptible to chromosome break because 
hypoacetylation can prevent proper replication response [363].Therefore, replication 
stress and fork restart are critical for preventing aberrant mitosis and senescence. 
1.2.7 Associated diseases 
Defects in replication fork maintenance proteins are associated with human 
diseases which contain common features such as developmental defects, premature 
aging, autoimmune disease, and cancer predisposition. The link between cellular 
senescence and premature aging is clear in several human diseases. As such 
dysregulation of ATR signaling, mutations in SPRTN, WRN, and FA proteins that 
contribute to cellular senescence are associated with human diseases featuring 
premature aging. Hypomorphic mutations in ATR or mutations in ATRIP are associated 
with Seckel syndrome characterized by microcephaly, developmental delay, and 
premature aging [364, 365]. Similarly, Ruijs-Aalfs syndrome is a progeroid syndrome 
characterized by premature aging, hepatoma development, and skeletal abnormalities 
caused by mutations in SPRTN [355, 366-368]. Furthermore, mutations in WRN are 
associated with Werner syndrome which is characterized by pre-mature aging but only 
by their second decade of life and has a high penetrance of age-related disorders such 
as type II diabetes and bilateral cataracts [369, 370]. Finally, mutations in Fanconi 




abnormalities, developmental delay, pre-mature aging and an increased cancer 
predisposition [371]. As expected, FA, Werner Syndrome, and Seckel syndrome patient 
cells all exhibit senescent features and endogenous replication stress markers like cell 
cycle arrest and micronuclei [372-374].  
Similarly, SAMHD1 and Pol η function are also linked to their human disease. 
Mutations in SAMHD1 cause the development of Aicardi-Goutières syndrome which is 
an inflammatory encephalopathy characterized by the increase in type 1 interferon 
production due to the enhanced cytosolic ssDNA production [375]. Mutations in Pol η 
are associated with Xeroderma pigmentosum variant (XP-V) characterized by sensitivity 
to sunlight [376]. Moreover, mutations in proteins ensuring proper replication through 
difficult genetic sequences can lead to developmental delays. For example, RTEL1 
stabilizes telomeric DNA by unwinding secondary structures like G-quadruplexes and 
prevents trinucleotide repeat expansion and fork breakage  [377, 378]. Therefore, 
RTEL1 mutant cells grow slower and display shortened telomeres  [379]. Notably, 
RTEL1 mutations cause while Hoyeraal Hreidarsson syndrome, a disorder 
characterized by immunodeficiency and developmental defects [380-383]. Additionally, 
naturally occurring genomic replication blocks are also associated with 
neurodevelopmental or neurodegenerative diseases [384]. Fragile X syndrome is 
characterized by expanded CGG repeats which can form fork impediments leading to 
chromosome breakage [385, 386].  
Mutations in ZRANB3 and SMARCAL1 are, also, associated with human 
diseases. Biallelic mutations in SMARCAL1 cause the autosomal recessive disorder 




the prominent features of renal failure, T cell immunodeficiency, spondyloepiphyseal 
dysplasia, growth retardation, facial dysmorphism, hyperpigmented macules, and 
microcephaly [186, 387-390]. More recently, mutations in ZRANB3 were associated with 
an African-specific type 2 diabetes implicating ZRANB3 in glucose response and insulin 
secretion in pancreatic β-cells [391]. 
Increased mutagenesis and chromosomal rearrangements are hallmarks of 
cancer. Therefore, mutations in several proteins involved with replication fork bypass 
and reversal are associated with cancer predisposition. For example, several TLS 
polymerases are associated with cancer progression [392-396]. Dysregulated 
expression of Pol κ is associated with colorectal and lung cancers [392-394]. While, 
overexpression of either Pol κ and Pol ι is associated with gliomas, with upregulation of 
Pol κ leading to a poorer prognosis [395]. Finally, overexpression of REV1 is associated 
with carcinogen-induced intestinal adenomas [396-398].  
Mutations in factors that promote fork reversal are also associated with cancer. 
HLTF is frequently silenced by promoter methylation in human colorectal and gastric 
cancers [399, 400]. Loss of Hltf is insufficient to induce cancer in wildtype mice but it 
significantly increases the formation of colon cancer in an Apc-mutant background 
[401]. Paradoxically, HLTF is also commonly amplified and overexpressed in 
esophageal, uterine and several types of squamous cell carcinoma [402]. HLTF 
overexpression is significantly associated with increased metastasis and poor prognosis 
in non-small cell lung cancer patients [403]. However, the putative functional role of 
HLTF amplification in cancer has not been experimentally investigated. Similarly, only a 




cancer. ZRANB3 was described as a putative tumor suppressor gene in endometrial 
cancer [397, 404]. SMARCAL1 mutations have been described as candidate drivers in a 
subtype of glioblastomas that are wildtype for TERT promoter and IDH1/2 and further 
enriched in ALT positive tumors [182].  In a T-cell lymphoma mouse model, loss of 
Smarcal1 impairs survival of hematopoietic cells and significantly reduces 
lymphomagenesis induced by gamma irradiation [405]. Similarly loss of either Smarcal1 
or Zranb3 increases replication stress and cell death induced by Myc overexpression 
and reduces Myc-driven B-cell lymphomagenesis [406]. 
1.4 The roles of BRCA1 and BRCA2 during double-strand break repair and 
fork protection 
1.4.1 Sources of double-strand breaks 
Endogenous and exogenous sources can cleave the phosphodiester backbone 
of the two strands of DNA generating a (DSB). Exogenous sources of DSBs include IR, 
clastogens (bleomycin and neocarzinostatin), and topoisomerase II-inhibitors 
(etoposides) [407]. Since the late1930’s, it has been known that IR can break 
chromosomes [408]. IR is defined as any subatomic particle that contains enough 
energy to strip electrons from atoms [407]. IR can generate a DSB directly by colliding 
with the DNA backbone or indirectly by colliding with water generating a reactive 
hydroxyl radical that can react with the nearby DNA, thus inducing a SSB [409]. Since a 
single IR particle can generate clustered lesions, two opposing SSBs near each other 
cause a DSB [410-412]. Hydrogen peroxide (H2O2), similarly generates SSBs through 




this way saturates at intermediate levels of H2O2 suggesting that there is a limiting factor 
of chromatin-bound metal ions that can be converted into a free radical [413]. 
Radiomimetic compounds induce a free radical attack on the DNA backbone [414, 415]. 
Activated bleomycins contain a reduced transition metal like iron or copper, oxygen, and 
often H2O2 leading to free radical attack [415]. Alternatively, bicyclic enediynes, like 
neocarzinostatin, removes hydrogens from the deoxyribose sugar on both DNA strands 
which can then react with water to generate a break in the sugar backbone [414]. 
Finally, etoposides generate DSBs by inhibiting topoisomerase II [416, 417]. 
Topoisomerase II generates a DSB transiently to relieve torsional stress from the 
unwinding DNA helix [418]. Etoposides prevent the re-ligation step of each 
topoisomerase II homodimer therefore, DSB formation requires the action of two 
etoposide molecules binding to each topoisomerase II monomers [419].  
Endogenous sources include replication stress, cellular metabolism (H2O2), or 
scheduled DSB generation by nucleases during V(D)J recombination and meiotic 
recombination [420]. As discussed above, replication fork collision with SSBs can 
generate a DSB and replication stress can also result in DSB formation upon reversed 
fork cleavage. The major source for H2O2 is oxidative phosphorylation occurring in the 
mitochondria [421, 422]. Finally, antigen receptor gene assembly (V(D)J) 
recombination) and meiotic recombination use programmed DSB formation in order to 
generate genetic diversity [423-425].  
Failure to or faulty repair of DSBs leads to chromosomal abnormalities, 
mutagenesis, and cell death [50, 426-428]. To avoid such consequences, the cell has 




1.4.2 The tumor suppressors BRCA1 and BRCA2 
The tumor suppressors BRCA1 (Breast Cancer Type 1) and BRCA2 (Breast 
Cancer Type 2) play an important role to maintain genome stability. Mutations in 
BRCA1 and BRCA2 together account for 25% of familial breast cancers [429] and 
predispose carriers to breast and ovarian cancers with a pattern of autosomal dominant 
inheritance [430-432]. BRCA1 is a large (220 kDa) nuclear protein containing an N-
terminal RING (Really Interesting New Gene) domain, a coiled-coil domain, and a 
tandem BRCT repeat that makes up the BRCT domain (Figure 1.5A) [433-438]. BRCA1 
forms an obligate heterodimer with BARD1 through their respective RING-domains that  
together make a functional E3 ubiquitin ligase (Figure 1.5A) [437, 439]. The BRCT 
domain of BRCA1 is a phosophoprotein binding domain allowing BRCA1 to exist in 3 
different mutually exclusive complexes: BRCA1-A, BRCA1-B, and BRCA1-C (Figure 
1.5A)  [440]. The A-complex is composed of the ubiquitin binding protein RAP80, the 
de-ubiquitinating enzymes BRCC36 and BRCC45, MERIT40 (Mediator of Rap80 
interactions and targeting 40), and phosphorylated Abraxas and plays an important role 
in mediating DNA damage-induced ubiquitin signaling and recruitment of BRCA1 to 
sites of double strand breaks (DSBs) [441-447]. The B complex consists of TOPBP1 
and phosphorylated BACH1 (FANCJ), a helicase that promotes replication stress 
induced cell cycle checkpoint and interstrand crosslink repair [448-451]. Finally, the C 
complex involves the MRN (MRE11-RAD50-NBS1) complex and phosphorylated CtIP 
and is critical for DSB repair by facilitating end resection [446, 452]. In addition to 
binding phosphoproteins, BRCA1 interacts with RAD51 and PALB2 (Partner and 




residues 758-1064 and 123-261 respectively [453, 454], while BRCA1 interacts with the 
scaffold protein PALB2 through its coiled coil domain which mediates the interaction 
between BRCA1 and BRCA2 (Figure 1.5)  [434, 455, 456]. 
BRCA2 is another large nuclear protein (384 kDa) with 8 tandem BRC repeats 
and 3 OB-folds (oligonucleotide/oligosaccharide-binding) with the helical domain making 
up the DBD (BRCA2 DNA/DSS1-binding domain) (Figure 1.5B) [457-459]. BRCA2 
plays a critical role in sequestering RAD51 monomers through the tandem BRC repeats 
and facilitating the generation of RAD51 nucleoprotein filaments during the repair of a 
DSB (Figure 1.5B) [460, 461]. Furthermore, BRCA2 and PALB2 interact to maintain the 
G2 checkpoint independently of their role in HR [462]. Therefore, both BRCA1 and 
BRCA2 play an important role in repairing DNA DSBs. 
1.4.3 BRCA1/2 and the repair of double-strand breaks 
Repair of a DSB is mediated by two main pathways: non-homologous end joining 
(NHEJ) and homologous recombination (HR). NHEJ is the predominant repair pathway 
occurring in all cell cycle phases while HR is restricted to the S and G2-phases of the 
cell cycle [463-465]. NHEJ is potentially an error-prone pathway that involves the direct 
-ligation of the damaged ends [466]. In contrast, HR is a relatively error-free pathway 
that involves the use of a sister chromatid or homologous sequence to repair the DSB 
[467, 468]. BRCA1 plays an important role in the choice between NHEJ and HR while 
both BRCA1 and BRCA2 facilitate HR.   
The role of BRCA1 in DNA repair pathway choice and the S and G2/M checkpoint 
Once a DSB is formed, the two ends of the break are rapidly bound by the 




[469-473]. During S-phase, the initiating step for HR is the binding of the MRN complex 
to the DNA end and DNA-PK removal [474]. The MRN complex mediates a 1-
dimensional search facilitated by RAD50 for free DNA ends while DNA-PK increases 
the ability of MRN to remove Ku70/Ku80 from the ends to allow MRN occupancy [474, 
475]. MRN then activates ATM leading to the phosphorylation of histone H2A.X on 
serine 139 (γH2AX) (Figure 1.6) [476]. MDC1 (mediator of DNA damage checkpoint 
protein 1) binds to γH2AX and recruits more MRN and ATM to further amplify the signal 
[477-479]. Activated ATM then phosphorylates MDC1, CHK2 (checkpoint kinase 2), and 
BRCA1 leading to the S and G2/M checkpoints while phosphorylation of p53 induces 
the G1 checkpoint [480-482]. In particular, ATM phosphorylation of BRCA1 on S1387 
leads to S-phase checkpoint while S1423 leads to G2/M checkpoint activation [483, 
484]. Phosphorylated MDC1 then recruits the E3 ligase RNF8 which polyubiquitinates 
the linker histone H1, primed by the E3 ligase HUWE1, leading to the recruitment of 
another E3 ligase RNF168 (Figure 1.6) [485-488]. RNF168 cooperates with RNF8 to 
ubiquitinate histone H2AK13/K15 leading to the recruitment of RAP80 and 53BP1 
(Figure 1.6) [489-492]. Binding of RAP80 on K63-linked H2AX recruits the BRCA1-A 
complex to DSBs to fine tune HR-mediated repair by preventing the over-accumulation 
of the BRCA1-B and C complexes [493, 494]. 53BP1 is a scaffold protein that binds to 
monoubiquitinated H2AK15 and di-methylated H4K20 (H4K20me2) and dimerizes on 
histones [495-497]. H4K20me2 marks pre-replicative DNA, therefore favoring 53BP1 
binding at un-replicated regions [498]. ATM phosphorylated 53BP1 interacts with RIF1 
and the Shieldin complex (Shld3, Rev7, Shdl1, and Shld2) [499-502] along with PTIP 




1.6) [503-505]. Therefore, BRCA1-BARD1 prevents NHEJ in two ways: by displacing 
53BP1 binding and counteracting RIF1 localization. BARD1 binds unmethylated H4K20, 
a mark of post-replicative DNA, along with directly binding mono-ubiquitinated H2AK15 
thereby excluding 53BP1 binding and localizing BRCA1 to DSBs (Figure 1.6) [506, 
507]. Notably, TIP60-mediated acetylation of residues neighboring H4K20 disrupts the 
ability of 53BP1 to bind H4K20me2 [508, 509]. BRCA1, on the other hand, directly 
counteracts RIF1 localization at DSBs (Figure 1.6) [510-514]. Additionally, SCAI 
(suppressor of cancer cell invasion) has been recently implicated to bind to 
phosphorylated S/T sites adjacent to proline (S/TP) on 53BP1 to prevent RIF1 binding 
and promote HR [515]. Ultimately the key step in driving HR is the generation of ssDNA 
at the break site by end resection. 
The roles of BRCA1 and BRCA2 during homologous recombination 
End resection is a bidirectional process that is initiated by the MRN complex and 
CtIP (Figure 1.7).  Specifically, the MRN complex binds next to DSB ends and is 
activated by CDK-phosphorylated CtIP [516-519]. MRE11 nicks the dsDNA and digests 
DNA towards the DSB using its 3’ to 5’ exonuclease activity while the 5’ to 3’ 
exonuclease EXO1 and the endo/exonuclease DNA2 along with the helicases BLM 
(bloom syndrome helicase) or WRN (Werner’s syndrome helicase) degrades the DNA 
away from the DSB to generate long ssDNA overhangs by long-range end resection 
(Figure 1.7) [520-524]. Notably, the CtIP endonuclease activity is only required in part 
for end resection on complex DNA ends generated by topoisomerase poisons or IR 
[525-527]. Additionally, end resection of breaks with modified bases or protein 




Following end resection, RPA rapidly coats the 3’-overhangs preventing the 
formation of secondary DNA structures and nuclease degradation (Figure 1.7) [529-
531]. Subsequently, BRCA1 through PALB2 recruits BRCA2 to the resected ends and 
promotes the loading of RAD51 onto ssDNA leading to strand evasion and repair of the 
DSB (Figure 1.7) [172, 434, 456, 532-535]. The BRCA1-BARD1 heterodimer then 
associate with the presynaptic RAD51 filament to promote DNA strand invasion into the 
homologous sequence and subsequent D-loop formation (Figure 1.7) [536]. Finally, 
HELQ, MCM8-9, and MCM8IP (HROB) facilitate D-loop extension and PCNA, DNA 
polymerase δ, and RFC-1D synthesize the DNA [242, 244, 537].  
1.4.4 BRCA1/2 and the protection of stalled forks from nucleolytic degradation 
BRCA1 and BRCA2 also play a HR-independent role in protecting replication 
forks from nucleolytic degradation after fork reversal [154, 214, 215]. Using the DNA 
fiber technique, the Jasin lab was the first to show that depletion of either BRCA1 or 
BRCA2 led to shorter nascent DNA tracts after replication stress [214, 215]. Abrogation 
of replication fork reversal prevented the degradation seen in BRCA1 or BRCA2-
deficient cells [154]. Interestingly, pretreatment of cells with cisplatin activates 
PRIMPOL leading to excessive repriming that prevents SMARCAL1-mediated fork 
reversal, suggesting that PRIMPOL also protects BRCA-deficient replication forks from 
degradation [538]. Furthermore, while the BRCT domain of BRCA1 plays a critical role 
in protecting replication forks and HR, the BRCT domain of BARD1 is only required for 
protecting replication forks by mediating BRCA1/BARD1 recruitment to stalled forks in a 
poly(ADP-ribose)(PAR)-dependent manner [217]. RPA phosphorylation, on the other 




promote fork protection [533, 539]. BRCA2 promotes replication fork stability through a 
RAD51 interaction site that, when mutated, does not alter the ability of BRCA2 to 
perform HR [215, 540]. Notably, it was identified that CDK phosphorylation of BARD1 at 
S114 promotes PIN1 isomerization of BRCA1 allowing enhanced binding of RAD51 and 
promoting fork protection [229]. It remains, however, to be determined how BRCA1 and 
BRCA2 act non-redundantly during fork protection. 
1.5 The role of stalled fork protection and homologous recombination in 
cancer predisposition 
Failure to properly repair DSBs or protect replication forks from extensive 
nascent strand degradation are associated with gross chromosomal aberrations, 
increased genomic instability, and increased mutational burden which are hallmarks of 
cancer [154, 209, 214-216, 226, 300, 541]. Germline mutations in the tumor 
suppressors BRCA1 and BRCA2 confer a lifetime risk for breast (72% and 69%, 
respectively) and ovarian (44% and 17%, respectively) cancer [542], as well as an 
increased risk for prostate and pancreatic cancers (predominantly by mutations in 
BRCA2) [543]. BRCA1/2-deficient cancers are associated with a broad distribution of 
base substitutions (mutational signature 3) and non-clustered deletions of less than 100 
kb (rearrangement signature 5), while BRCA1-loss is additionally associated with small 
tandem duplications of less than 10 kb (rearrangement signature 3) [544, 545]. 
Homozygous loss of BRCA1 or BRCA2 is embryonic lethal suggesting that 
BRCA1 and BRCA2 are required for normal embryonic development [546-548]. As 
previously discussed, BRCA1 and contribute to both replication fork protection and the 




observed in BRCA1/2-mutant carriers indicating that haploinsufficiency increases 
genomic instability, therefore leading to an increased propensity to lose the wild type 
allele [549, 550]. While heterozygous mutant BRCA1 (BRCA1mut/+) cells are functional 
for HR they show defects in stalled replication fork protection [551]. Similarly, 
heterozygous mutant BRCA2 (BRCA2mut/+) cells also displayed fork protection defects 
[552]. However, there is still a debate about the relative contributions of HR-mediated 
repair and fork protection functions of BRCA1/2 to tumor suppression. Feng and 
colleagues demonstrated that the HR function of BRCA2 prevents under-replication, 
while fork protection plays a minor role in the suppression of replication stress [540].  
Normally, the p53 pathway becomes activated in response to unrepaired DNA damage 
and replication stress, leading to cell cycle arrest, senescence or apoptosis [553]. 
Bypass of senescence appears to be a key step in BRCA1/2-deficient breast and 
ovarian tumorigenesis. In agreement with this premise, BRCA1mut/+ human mammary 
epithelial cell lines experience increased DNA damage, telomere erosion and premature 
senescence that can be bypassed by loss of p53 or pRb [554]. Furthermore, p53, pRb, 
and p16 are frequently mutated or lost in BRCA-deficient breast cancers [555-558]. 
Loss of the p53 axis enables the loss of second BRCA1/2 allele. Ultimately, loss of both 
alleles is associated with defects in both stalled fork protection and HR [214, 215, 535, 
559, 560]. These observations support a model in which stalled fork protection and HR 
contribute to tumor suppression in distinct stages [217, 551, 561]. In this case, 
heterozygous mutations would drive genomic instability by defective stalled fork 




HR-deficient cells which would drive an increase in genomic instability and drive 
malignancy [217]. 
Besides BRCA1/2, several other DNA repair factors are mutated in cancer. 
Germline mutations in the BRCA1 partner BARD1 have been identified as a pathogenic 
lesion in hereditary breast and ovarian cancers [562]. Additionally, biallelic mutations in 
the BRCA1/2-interacting protein PALB2 predispose carriers to breast and ovarian 
cancer, Wilms’ tumors and medulloblastoma [563, 564]. Monoallelic germline mutations 
in the RAD51 paralogs RAD51C and RAD51D predispose carriers to breast and ovarian 
cancers [565-568]. BLM also plays a role in both promoting HR and fork restart by 
counteracting RAD51 [218, 569]. This function of BLM to counteract RAD51 is distinct 
from its ability to prevent elevated sister chromatid exchange by dissolving double 
Holliday junctions formed during HR [569, 570]. Loss of function mutations in BLM 
cause Bloom’s syndrome which is characterized by an increased risk of early onset 
cancer development for several cancer types including leukemias, lymphomas, and 
colorectal cancers [571]. These studies underscore the importance between maintaining 
genomic stability through HR and fork protection and preventing tumor development.  
1.6 The role of stalled fork protection and homologous recombination in 
cancer therapeutics 
1.6.1 Chemosensitivity 
Targeting the vulnerabilities of cells defective for HR or fork protection is a 
promising therapeutic strategy for treating several cancer types. A study by Heeke et al. 




genes and determined that these mutations were detected in 17.4% of all solid tumors 
tested [572]. Therefore, treatments that can cause lesions that will be repaired by HR in 
normal tissues but will increase genomic instability and cell death in malignant HR 
mutant cells are currently being used for treating cancer. For instance, since the 1970’s 
the main line treatments for HR-deficient ovarian cancers have been platinum-based 
therapies, such as cisplatin and carboplatin [573]. Furthermore, agents that induce the 
formation of DSBs, which are typically repaired by HR, are also effective against HR-
deficient cancers including ionizing radiation, radiomimetics (bleomycin), topoisomerase 
I inhibitors (camptothecin, topotecan), and topoisomerase II inhibitors (doxorubicin, 
etoposide) [573, 574]. Additionally, the fork stalling agent, gemcitabine, is also an 
approved cancer treatment in combination with IR and platinum-based therapies [575]. 
Because gemcitabine is a chain-terminating nucleoside analogue and a ribonucleotide 
reductase inhibitor, it is possible that the increased DNA damage induced by this agent 
is due to replication fork stalling and excessive degradation, but this agent has not yet 
been used in fork degradation experiments.  
Notably poly(ADP-ribose) polymerase (PARP) inhibition has been demonstrated 
to sensitize BRCA1/2-deficient tumors [576-578]. Single strand breaks (SSBs), one of 
the most common DNA lesions, are typically sensed by PARP1 and PARP2 and 
stimulate SSB repair [579, 580]. PARP inhibition traps the PARP proteins onto the DNA 
resulting in both unrepaired SSBs that can be converted into DSBs during replication 
and replication fork collapse due to replication stalling and premature fork restart by 




protection to genomic stability and cellular viability. In fact, PARP inhibition can be 
synergistic with inhibitors for either HR or cell cycle checkpoint. 
PARP trapping increases replication fork stalling [582]. In response to replication 
stress the ATR-Chk1 pathway promotes fork slowing and prevents origin firing [583, 
584]. Therefore, loss of the ATR-Chk1 checkpoint could increase the sensitivity of HR-
deficient cells to PARP inhibitors (PARPis) by increasing DSBs by fork collapse. 
Consistent with this idea, ATR or CHK1 inhibition increases the sensitivity of cells to 
PARP inhibition [585, 586]. Furthermore, the ATM-CHK2 pathway is activated by DSBs. 
ATM inhibition and CHK2 inhibitors also sensitize cells to PARP inhibition [587, 588]. 
Therefore, clinical trials using checkpoint kinase inhibitors in combination with PARPis is 
warranted. Moreover, CtIP promotes HR and low levels of CtIP expression is associated 
with lower survival rates in breast cancer [589]. It has been demonstrated that CtIP 
depletion increases HR-deficiency in the breast cancer cell line MCF7 and sensitizes 
them to PARPis [589]. Therefore, CtIP inhibitors in combination with PARP inhibition 
may be a promising therapy. 
In addition to PARPis, other synthetic lethal combinations are currently under 
investigation. Alternative end-joining by Polθ (Theta-mediated end joining) acts 
predominantly in HR-deficient tumors [104, 590, 591]. Therefore, inhibition of Polθ is a 
promising anticancer therapy for HR-deficient tumors [592]. Another synthetic lethal 
combination was identified between BRCA-deficiency and RAD52 [593-595]. As such, 
RAD52 inhibition caused additional sensitivity of BRCA1-deficient cells to PARP 
inhibition [596]. Interestingly, RAD52 inhibition synergizes with Polθ inhibition to 




a synthetic lethal screen revealed that depletion of FEN1 or APEX2 increase lethality in 
BRCA1/2-deficient cells suggesting that inhibition of those factors could be a viable 
avenue for BRCA1/2-deficient tumors [598]. Additionally, the abrogation of the cell-cycle 
checkpoints alone sensitizes HR-deficient tumors due to an accumulation of DNA 
damage leading to cell death and therefore these agents are currently in early clinical 
trial evaluation for BRCA-mutated cancers as a monotreatment [573, 599]. Ultimately, 
the characterization of factors that increase genomic instability and cell death when 
inhibited in HR-deficient tumors will be of clinical importance.  
1.6.2 Chemoresistance 
Chemotherapeutic resistance is the ability of malignant cells to evade or resist 
the effects of cancer therapies. Through genomic instability driven rapid evolution, 
cancer cells can develop mechanisms to survive therapeutics leading to cancer relapse 
after remission, rapid disease progression, and ultimately poorer survival outcomes 
[600-602]. As previously described tumors harboring BRCA1/2 mutations are 
hypersensitive to DNA-damaging treatments, such as platinum-based chemotherapy 
and PARPi. However a large fraction of BRCA1/2 mutant patients eventually acquire 
resistance to these treatments [577, 578, 603, 604]. Specifically, the recurrence rates 
for ovarian cancer is 85% while the recurrence rate for breast cancer is 30% [605-607]. 
One explanation is that HR-deficient tumors can establish genomic stability and acquire 
chemoresistance through the restoration of HR. As such, secondary mutations in HR 
pathway genes such as the RAD51 paralogs RAD51C and RAD51D or reversion 
mutations in BRCA1 or BRCA2 have been associated with platinum resistance for 




HR promoting factors can aid in tumor cell survival to high levels of DNA damage. 
Therefore, increased RAD51 expression correlates with chemoresistance [611-614]. 
Additionally, high levels of MRE11, RAD50, or NBS1 reduce DNA damage and are also 
correlated with chemoresistance and poor prognosis in gastric cancer [615, 616]. 
Moreover, HELQ, a helicase that promotes the postsynaptic steps of HR, when 
overexpressed, is associated with resistance to cisplatin [242, 617, 618]. Finally, 
increased expression of the histone acetyltransferase TIP60 in nasopharyngeal 
carcinoma cell lines has been demonstrated to promote both HR and HR gene 
expression leading to cisplatin resistance [619].  
On the other hand, re-establishing end resection can also restore HR. In this 
case, loss of the shieldin complex or 53BP1 increased resistance of BRCA1-deficient 
tumor cells to PARP inhibition [620, 621]. Alternatively, aberrant NHEJ in HR-deficient 
cells can drive genomic instability and lethality. Notably, inhibiting NHEJ (by depleting 
Ku80, Artemis, or DNA-PKcs) in BRCA-deficient cells exposed to PARPi or FANCD2-
deficient cells exposed to platinum treatment prevents lethality and drives resistance 
[622, 623]. In agreement with the hypothesis that inhibiting NHEJ in HR-deficient tumor 
can drive resistance, loss of 53BP1in BRCA1-mutant mammary tumors led to PARPi 
resistance in mice [624].  
Remarkably, about half of all BRCA2-mutant cancers developed 
chemoresistance in the absence of HR-restoration suggesting the presence of an HR-
independent resistance mechanism [625]. In line with this hypothesis, the restoration of 
fork protection in addition to or independently from HR functionality in BRCA1/2-




overexpression which suppresses fork instability has been demonstrated to confer 
PARPi resistance [626]. Additionally, loss of the SNF2-fork remodeler SMARCAL1 
restores fork stability in BRCA1/2-deficient cells and confers PARPi resistance [154]. 
Similar observations have been reported for loss of PTIP, the SNF-2 family helicase 
CHD4, RADX, and EZH2 which are involved in promoting nascent strand degradation at 
stalled forks [175, 240, 627]. Notably, decreased CHD4 expression correlates with 
poorer prognosis for patients with BRCA2-mutant cancers [627]. Activation of alternative 
and compensatory DNA repair pathways in response to replication stress adds a further 
layer of complexity. It has been recently reported that BRCA1-deficient ovarian cancer 
cells adapt to recurrent cisplatin treatments by activating PRIMPOL-mediated repriming 
of stalled forks to protect BRCA1-deficient cells from nucleolytic degradation [538]. In 
addition, repriming appears as a general alternative mechanism to SMARCAL1- or 
HLTF-mediated fork reversal for the restart of DNA synthesis, at the expense of the 
formation of ssDNA gaps [538, 628]. These small ssDNA gaps may undergo resection 
and RAD51-mediated HR for proper post-replicative repair [629]. In line with these 
observations, HR-defective BRCA1-mutant cancer cells adapt to recurrent cisplatin 
treatment by activating PRIMPOL-mediated repriming to avoid excessive fork 
remodeling-induced nucleolytic degradation of nascent DNA at the expense of the 
formation of ssDNA gaps[538]. Additionally, loss of HLTF promotes discontinuous DNA 
synthesis by PRIMPOL [628]. TLS has been suggested as a third interconnected 
mechanism, along with fork reversal and repriming, to promote the restart of stalled 
forks [628]. Aberrant activation of the TLS pathway by FANCJ mutation, reduces fork 




[630]. Moreover, in HLTF mutant cells that cannot bind the 3’-end of ssDNA, HIRAN 
mutants, REV1 promotes fork progression by continuous DNA synthesis [628]. TLS also 
provides an alternative mechanism to HR for the post-replicative repair of ssDNA gaps 
generated during replication stress [631, 632]. Interestingly, genomic sequencing and 
analysis of mutational signatures in syngeneic cells treated with genotoxin agents 
suggest an up-regulation of TLS after BRCA1 depletion [633]. Taken together these 
recent findings shed new lights on the complex network of factors involved in 
remodeling, protection, and repair of stalled forks. Understanding the complex interplay 
between fork remodeling, repriming, TLS and HR in response to replication stress will 
be of utmost importance for developing novel cancer therapies. 
1.6.3 Immunotherapy 
Innate immunity is an evolutionary conserved cell-intrinsic reaction to microbial 
pathogens, which involves multiple mechanisms, and sensor molecules. Cytosolic DNA 
sensing recognizes and reacts to foreign DNA found in the cytoplasm (e.g., viral DNA), 
leading to immune responses. The cGAMP synthase (cGAS)–stimulator of interferon 
genes (STING) pathway has been identified as a critical component of DNA sensing 
[634]. Briefly, cytosolic DNA sensed by cGAS activates STING, which triggers the 
expression of interferon-stimulated genes (ISGs) and induces the inflammatory 
response (Figure 1.4) [634, 635].  
Recent studies have shown that unresolved DNA damage derived from 
replication fork instability, telomere fragility, common fragile site expression and 
chromosome mis-segregation often results in the formation of micronuclei upon mitotic 




induction of innate immune signaling [636-638]. Accordingly, micronuclei formed as a 
result of deficiency in BRCA1/2 or RAD51 activate innate immune signaling, and this 
response is exacerbated by PARP inhibitor treatment [639-643]. Notably, loss of the 
SNF2-family members SMARCAL1 and ERCC6L has been associated with an increase 
of micronuclei formation [185, 302]. However, it remains to be determined whether 
deficiency of these factors leads to innate immunity induction. 
In addition to micronuclei, short species of genomic DNA released into the 
cytoplasm during DNA replication and repair can also be recognized by cGAS, thereby 
triggering the activation of innate immune signaling. In particular, it was shown that 
cytoplasmic ssDNA derived from replication fork intermediates following HU treatment is 
degraded by TREX1 [356], a nuclease that suppresses innate immune signaling and 
maintains immune tolerance [644, 645], thus providing direct evidence that processing 
of stalled forks can generate cytoplasmic DNA and activate innate immunity. Additional 
studies have shown that the innate immune response is activated also by cytoplasmic 
ssDNA generated upon treatment with other replication stress-inducing agents, such as 
mitomycin C and cisplatin, or in response to IR  [646]. Of note, depletion of nucleases 
such as DNA2 and EXO1, but not MRE11 and CtIP, restrains innate immune signaling, 
suggesting that ssDNA molecules that induce innate immunity require extensive DNA-
end resection activities [646]. In addition, loss of SAMHD1, a factor that stimulates the 
exonuclease activity of MRE11 at stalled forks, was shown to prevent nascent DNA 
degradation at reversed forks and stimulate the helicase and endonuclease activities of 
RECQ1 and MRE11, respectively, thus resulting in the accumulation of cytosolic ssDNA 




Cytoplasmic ssDNA fragments deriving from stalled replication intermediates and 
cGAS-STING-dependent innate immune signaling have also been observed in BRCA1-
deficient breast cancer cells, although it remains unclear whether this phenotype is 
dependent on defective fork protection, as in the case of RAD51-depleted cells [641, 
647]. Interestingly, it was reported that prostate cancer cells accumulate cytoplasmic 
dsDNA derived from nascent DNA in a manner dependent from MUS81, suggesting that 
it may originate from the cleavage of stalled forks [359]. Further studies are required to 
understand the relationship of fork remodeling with cytosolic DNA sensing and 
inflammation and evaluate whether inhibition of SMARCAL1, ZRANB3, and HLTF may 
stimulate the cGAS-STING pathway. Overall, the above findings demonstrate that 
replication fork instability leads to aberrant inflammatory response in both malignant and 
non-malignant cells (Figure 1.4).  
cGAS-STING-dependent innate immune signaling enhances tumor 
immunogenicity, and consequently the response of tumors to immunotherapies, such as 
immune checkpoint blockade (ICB) therapies that use antibodies inhibiting the immune 
checkpoint factors PD-1, PD-L1 and CTLA-4 [648-671]. High PD-L1 expression on 
tumor cells restricts T-cell activity by binding to the PD-1 receptor on tumor infiltrating T-
cells representing a tumor adaptive immune response [672-674]. Notably, the 
expression of PD-L1 depends upon STING activation and is induced in response to 
replication stress [647]. Importantly, in the context of ICB therapy, higher levels of PD-
L1 on tumor cells correlate with better response to PD-1/PD-L1 antibody-mediated 
immunotherapy [675]. STING activation in response to replication stress can also result 




tumor-infiltrating cytotoxic T cells [639], as well as type-I interferon signaling, which 
promotes anti-tumor immunity [676-678]. However, recent studies have also shown that 
activation of the cGAS-STING pathway in chromosomally unstable tumors drives 
metastasis [679]. Understanding the connection between replication fork instability and 
the cGAS-STING pathway will therefore be critical for defining underlying mechanisms 
of anti-tumor immunity and metastasis and predicting the response to ICB therapy in 
cancer patients (Figure). 
1.7 The chromatin remodeler SMARCAD1 
SMARCAD1 (SNF2 family ATPase SWI/SNF-related, matrix-associated actin-
dependent regulator of chromatin, subfamily A, containing DEAD/H Box-1) is another member 
of the INO80 sub-family of SNF2-family chromatin remodelers [265, 266]. SMARCAD1 
is a ubiquitously expressed protein involved in DNA repair, heterochromatin 
maintenance, transcription, and pluripotency [680-688]. SMARCAD1 is conserved from 
yeast and structurally contains N-terminal tandem CUE (coupling ubiquitin to ER 
degradation) domains and a C-terminal SNF2-like helicase domain (Figure 1.8) [680]. 
While full-length SMARCAD1 (1026 amino acids) is expressed in all tissues, a truncated 
isoform of SMARCAD1 (600 amino acids) lacking the CUE domains is expressed in skin 
fibroblasts and to a lesser extent in keratinocytes and esophageal tissues [689, 690]. 
Mutations in the skin-specific isoform causes an autosomal dominant form of 
adermatoglyphia and Basan syndrome due to altered epidermal differentiation-
associated gene expression [689-692]. Strikingly, SMARCAD1 has been demonstrated 
to promote pancreatic and breast cancer cell growth and metastasis in vitro [693-695] 




SMARCAD1 expression is elevated in mammary, embryonal, and lymphoid tumors 
[697]. Additionally elevated expression correlates with poor pancreatic cancer prognosis 
[695, 697]. However how mechanistically SMARCAD1 may promote tumorigenesis is 
still poorly understood. 
KAP1 (KRAB (Krüppel associated box)-associated protein 1) is the major binding 
partner of SMARCAD1 which is pulled-down in equivalent stoichiometric amounts [680]. 
While CUE domains typically act as ubiquitin binding domains, the tandem CUE 
domains of SMARCAD1 have recently been implicated to mediate interaction with KAP1 
(Figure 1.8) [698]. Both KAP1 and SMARCAD1 play an important role in maintaining 
heterochromatin during replication (Figure 1.9A) [680]. SMARCAD1 directs histone 
deacetylation by the coordinated actions of its binding partners histone deacetylases 
HDAC1 and HDAC2 and promotes histone methylation by its interactor histone 
methyltransferase G9a/GLP (Figure 1.9A) [680]. KAP1 interacts with Suv39h1 to 
reinstate the tri-methylation of histone H3K9 after replication (Figure 1.9A) [699]. Di-and 
tri-methylated histone H3K9 has been implicated in HP1 binding and heterochromatin 
formation [700, 701]. SMARCAD1 acts at sites of replication through its interaction with 
PCNA, although no canonical PCNA interaction motif has been identified so far [702]. 
Strikingly, heterochromatin maintenance is a conserved function with the fission yeast 
ortholog Fft3 [703] and the budding yeast ortholog Fun30 [704]. In addition to 
SMARCAD1’s role at the replication fork, SMARCAD1 facilitates DNA repair. 
SMARCAD1 also contributes to the completion of mismatch repair (MMR) and 
HR. The MMR pathway recognizes and repairs mis-paired bases following replication in 




(MSH2 and MSH3) [705-708]. SMARCAD1 facilitates MMR by promoting nucleosome 
exclusion in a MSH2-dependent manner in Xenopus egg extracts and HeLa cells 
(Figure 1.9B) [680, 685, 688]. This is mediated by SMARCAD1’s interaction with MSH2 
and MSH6 [680, 685]. How SMARCAD1 excludes nucleosomes during MMR, however, 
is still unknown. With regards to HR Fun30 has been shown to play a role in promoting 
Exo1-mediated long-range end resection, but the mechanism of SMARCAD1-mediated 
end resection is less understood (Figure 1.10) [681, 709-712]. Fun30 has been 
extensively demonstrated to facilitate Exo1 long-range end resection by counteracting 
the 53BP1 homolog, Rad9, and is recruited to sites of DNA damage through CDK-
phosphorylation dependent binding to the TOPBP1 homolog, Dpb11 [681, 709, 713, 
714]. Fun30 has a higher affinity for and is activated by ssDNA bound nucleosomes 
providing a potential mechanism for short-range resection as a means of activating 
Fun30 mediated remodeling [712]. Furthermore, purified Fun30 can slide nucleosomes 
in an ATP-dependent manner in vitro [715]. SMARCAD1 and Fft3 have recently been 
shown to mediate long-range end resection [681, 682, 716]. In particular, SMARCAD1 
has been demonstrated to be recruited to sites of laser or Fok1-mediated DSBs in 
human osteosarcoma cell lines [681]. Additionally, depletion of SMARCAD1 reduced 
ssDNA formation after IR and SMARCAD1-depleted cells were defective in gene 
conversion from an I-SceI-induced DSB [681]. In contrast to the tandem CUE domains 
binding to KAP1, Densham et al. suggested that the CUE domains recruit SMARCAD1 
to DSBs by binding to BRCA1/BARD1 mediated H2A ubiquitination leading to 
displacement of 53BP1 from the break [682]. While this may be an attractive hypothesis 




domains have a higher affinity for KAP1 than mono-ubiquitin [698]. Second, the 
enzymatic activity of the BRCA1/BARD1 ubiquitin ligase is not essential for HR or tumor 
suppression [717, 718]. Finally, SMARCAD1 phosphorylation by ATM and stabilization 
through RING1-mediated ubiquitination are critical for SMARCAD1 recruitment to and 
function at DSBs (Figure 1.8) [686]. This indicates that SMARCAD1 does not require 
histone ubiquitin-binding for recruitment. In fact, ATM phosphorylated-KAP1 has also 
been implicated in decondensing chromatin during HR in order to facilitate end 
resection [719, 720]. Taken together, these studies may support a mechanism in which 
KAP1 and SMARCAD1 act together to facilitate chromatin de-condensation during HR, 
thus promoting end resection. How SMARCAD1 and KAP1 decondense the chromatin 
during HR, however, is still not known. 
1.8 Objectives  
Replication stress poses a risk to the fidelity of DNA replication and eventually 
contributes to genomic instability and mutagenesis. Replication fork reversal is a 
frequent protective mechanism during replication stress that allows forks to resume 
DNA replication without chromosomal breakage [154]. HR factors, such as BRCA1, 
BRCA2, BARD1, RAD51, have been found to play a protective role by preventing fork 
degradation on these reversed forks [214, 215, 217]. Recently, Lopes and Penengo 
have characterized nucleosomes on the reversed arm of the forks [318]. These 
nucleosomes have been suggested to pose a barrier to resection [228, 318]. Therefore, 
how nucleases may counteract chromatin deposited on the reversed arm of the fork is 




Another unanswered question is about the possible role of SMARCAD1 during 
replication stress. Unlike SMARCAD1, Fun30, has been demonstrated to play a role in 
DNA damage tolerance after replication stress [721, 722]. fun30Δ yeast are sensitive to 
replication stress agents like MMS and HU [721, 722]. Furthermore, in yeast lacking the 
HLTF/SHRPH ortholog, Rad5, Fun30 contributed to replication stress sensitivity 
suggesting that Fun30 negatively regulates HR-mediated repair at the fork [721]. 
Additionally, Fft3 has recently been demonstrated to be required for replication fork 
resection and restart [723]. Moreover, like Fun30, fft3Δ yeast are sensitive to MMS 
[723]. While SMARCAD1 promotes HR through long-range end resection and is 
associated with the replisome, it is not known whether SMARCAD1 plays a role during 
replication stress.  
Therefore, we hypothesize that SMARCAD1 may promote nucleolytic 
degradation by remodeling the chromatin on the regressed arm of the replication fork. 
This is based on these four observations: 1) nucleosomes are present on the regressed 
arm of the fork, 2) SMARCAD1 promotes end resection during HR, 3) SMARCAD1 
stably associates with the replication fork, and 4) the yeast orthologs, Fun30 and Fft3, 
play a role during replication stress. To test this hypothesis, we sought to use BRCA1/2-
deficient mammary epithelial cell lines. Loss of either BRCA1 or BRCA2 in replication 
stress leads to replication fork degradation [214, 215]. As such, if SMARCAD1 promotes 
replication fork resection, then loss of SMARCAD1 can prevent nascent DNA 
degradation in these cells. Consequently, the objective was to elucidate a new function 






Figure 1. 1 
Mechanisms of fork restart upon replication stress. When the replication machinery encounters 
a replication block (stop sign), replication fork progression stalls, leading to the formation of single-
stranded DNA (ssDNA) that is rapidly coated by the RPA trimer (I). Restart of stalled forks can occur 
through lesion bypass by translesion synthesis or fork repriming (II-III). Translesion synthesis allows the 
direct bypass of the DNA lesion (II), while fork repriming promotes the restart of DNA synthesis 
downstream of the lesion (III). Alternative to lesion bypass, stalled forks can undergo reversal mediated 
by fork remodelers, including the SNF2-family members SMARCAL1, ZRANB3 and HLTF (IV). Fork 
reversal slows down replication fork progression, thus allowing sufficient time for repair of the lesion. 
Reset of reversed forks can then promote the restart of DNA synthesis once the lesion has been removed 
(V). Fork reversal could also directly promote the bypass of the DNA lesion by enabling DNA synthesis on 
the nascent DNA strand of the sister chromatid (green) through template switching. Following fork 
reversal, the exposed ends of the regressed fork are stabilized by RAD51 to prevent extensive 
degradation by the nucleases MRE11, DNA2 and EXO1 and protect the integrity of the fork (IV). 
BRCA1/2, RAD51 paralogs and Fanconi anemia proteins cooperate with RAD51 to maintain fork 
protection. Defective fork protection causes extensive fork resection and processing of the regressed fork 
by the endonucleases SLX4 and MUS81, leading to fork collapse (VI). Fork collapse can also result from 
MUS81-mediated cleavage of persistently arrested stalled forks or from replication forks encountering 
single-strand DNA breaks. Collapsed forks are repaired by HR-mediated fork restart pathways dependent 









Figure 1. 2 
The SNF2-family of proteins. SNF2-family sub-family relationships based on the domain alignments 
of the helicase region adapted from Flaus et al. [265] (not to scale). Alongside the alignments are the 
schematic representations of the protein domains for the family members (not to scale). All SNF2-family 
members contain a helicase domain consisting of DEXDc and HELICc motifs. Unlike other SNF2-family 
members, INO80-like proteins contain a large insertion within the helicase domain. The SMARCA-like 
group consist of SMARCA2 (1590 aa) and SMARCA4 (1647 aa). The ISWI-like group consists of 
SMARCA1 (1054 aa) and SMARCA5 (1052 aa). The CHD-like group consists of CHD1 (1710 aa), CHD2 
(1828 aa), CHD6 (2715 aa), CHD7 (2997 aa), CHD8 (2581 aa), CHD9 (2897 aa), CHD3 (2000 aa), CHD4 
(1912 aa), and CHD5 (1954 aa). CHD3, CHD4, and CHD5 have N-terminal plant homeodomain (PHD) 
fingers not represented in the schematic. The INO80-like group consists of INO80 (1556 aa) and 
SMARCAD1 (1026 aa). INO80 has an N-terminal PHD domain, while SMARCAD1 has two coupling of 
ubiquitin to ER degradation (CUE) motifs not represented in the schematic. The RAD54-like group 
consists of RAD54L (747 aa), HELLS (838 aa), and ATRX (2492 aa). SMARCAL1 (954 aa), ZRANB3 
(1079 aa) and HLTF (1009 aa) (in red) are the only SNF2-family members that have been currently 
shown to regress stalled replication forks in vivo. HLTF contains a RING domain that mediates the 
interaction between HLTF and the substrates to ubiquitinate. SMARCAL1 harbors an RPA2-binding motif 
to directly interact with RPA. ZRANB3 contains a PCNA-interacting protein (PIP) motif, AlkB homolog 2 
PCNA interacting motif (APIM) and an NZF domain that cooperate to bind polyubiquitinated PCNA. The 
HARP, HIRAN, and SRD (substrate recognition) domains of HLTF, SMARCAL1, and ZRANB3, 






Figure 1. 3 
Methods for studying replication fork transactions. Overview of the current techniques used 
to (1) monitor replication fork dynamics and visualize replication fork structures, (2) identify 
protein associated with and localized on nascent DNA, (3) monitor locus-specific replication fork 
progression, (4) study DNA lesion bypass and repair events at replication fork barriers, and (5) 
reconstitute replication fork transactions in vitro. DNA fibers and DNA combing techniques 
enable the monitoring of individual replication fork progression, while electron microscopy allows 
high-resolution detection of DNA intermediates and replication fork structures, such as reversed 
forks and ssDNA gaps. Protein identification and localization on newly synthesized DNA can be 
monitored by iPOND (isolation of protein on nascent DNA), PLA-based approaches, and by 
super-resolution microscopy methods, such as STORM (stochastic optical reconstruction 
microscopy). Techniques, such as SMARD (single molecule analysis of the replicated DNA), 
nanopore-based sequencing methods (D-NAscent, Fork-seq), and optical mapping enable the 
study of replication fork dynamics at genomic loci of interest. Antibody-labeled DNA lesions or 
programmable barriers, such as the E. coli Tus-Ter system, enable the analysis of events 
occurring when replication forks encounter obstacles. Xenopus egg extracts can be utilized to 
study replication fork progression, and bypass and repair of DNA lesions. Similar studies can be 
conducted using purified replication factors that enable DNA synthesis in vitro. Purified proteins 
can also be utilized to detect enzymatic activities on fork-like substrates or define DNA 
transactions at single-molecule level using DNA curtains or optical tweezers technologies 






Figure 1. 4 
Cellular effects induced by replication stress. Failure to complete DNA replication due to 
replication stress results in under-replication and sister-chromatid bridge formation. If the bridges are not 
resolved during anaphase, the sister chromatids remain attached to each other, resulting in chromosome 
mis-segregation, lagging chromosome formation, or chromosome breakage. Chromosomal breakage and 
mis-segregation results in the formation of chromosomal aberrations. Chromosomal fragments or lagging 
chromosomes that fail to be incorporated into the daughter cell nucleus form micronuclei. Errors during 
DNA synthesis and DNA repair processes can result in the inaccurate duplication of the genome and 
mutagenesis. Cytoplasmic DNA fragments and micronuclei originating upon replication stress may be 
recognized by the cGAS-STING pathway, leading to the induction of interferons, immune-stimulated 
genes (ISGs), and immune checkpoint factors (e.g., PD-L1). PD-L1 expression inhibits immune cell 









Figure 1. 5 
Domain organization and binding partners of BRCA1 and BRCA2. Schematic overview of the 
functional domain organization for BRCA1 and BRCA2 (not to scale). Both BRCA1 and BRCA2 contain 
nuclear localization signal (NLS) residues to promote their import into the nucleus. (A) BRCA1 interacts 
with its obligate heterodimer BARD1 through its N-terminal RING (Really Interesting New Gene) finger 
domain conferring E3 ubiquitin ligase activity. CHK2 phosphorylates BRCA1 on serine 988 (S988) and 
ATM phosphorylates S1387, S1423, and S1524 to promote BRCA1 function during homologous 
recombination (HR). A region spanning between amino acids 758-1064 facilitate BRCA1 interaction with 
RAD51 to promote strand invasion during HR. The coiled-coil domain enables the interaction between 
PALB2 an associate of BRCA2 (as indicated by the light green box). The phosphor-binding BRCT domain 
enables BRCA1 association with phosphorylated Abraxas, BACH1, and CtIP to form the BRCA1-A, 
BRCA1-B, and BRCA1-C complexes, respectively. (B) BRCA2 associates with PALB2 at the N-terminus 
at amino acid residues 21-39. BRCA2 contains eight BRC repeats that bind RAD51 monomers spanning 
amino acid residues 1009-2083. The DNA binding domain (DBD) consists of a helical domain (dark 
orange) and three OB-folds along with a tower domain (light orange) facilitating BRCA2 binding to DNA. 

















Figure 1. 6 
DNA double strand break repair pathway choice. DNA double strand break (DSB) ends are 
rapidly coated by the Ku70/Ku80 heterodimer and the MRE11 (M), RAD50 (R), NBS1 (N) complex. 
Binding of the MRN complex recruits ATM which phosphorylates several targets including itself and H2AX 
to form γH2AX. γH2AX is bound by MDC1 that bind additional MRN and ATM providing a feedback loop 
and amplification of the γH2AX signal. RNF8 binds MDC1 and cooperates with HUWE1 to poly-
ubiquitinate the linker histone H1 leading to the recruitment of RNF168 and ubiquitination of H2AK15. In 
G1 and early S-phase there is low CDK-activity and a high amount of histone H4K20me2 marking pre-
replicative DNA. While in late S-phase through G2 there is high CDK activity and low H4K20me2. 53BP1 
binds both H4K20me2 and H2AK15ub enabling the recruitment of PTIP, RIF1, and the Shieldin complex 
which restricts resection and promotes non-homologous end joining (NHEJ) mediated by DNA-PKcs and  
Ku70/Ku80 (DNA-PK), DNA ligase IV and the XRCC4 complex (XRCC4 and XLF). High CDK activity 




BRCA1 to DSBs preventing 53BP1 and RIF1 accumulation, thereby promoting end resection. Extensive 













Figure 1. 7 
The roles of BRCA1 and BRCA2 during homologous recombination. Double strand breaks 
(DSBs) are rapidly sensed and bound by the MRN complex (MRE11, RAD50, and NBS1). The MRN 
complex recruits CtIP which is then phosphorylated by CDK leading to initial end resection by the MRN 




generates long 3’-single stranded (ssDNA) overhangs. The ssDNA is then coated by the RPA trimer 
(RPA1, RPA2, and RPA3) to prevent DNA reannealing. BRCA1-BARD1-PALB2-BRCA2 facilitate the 
exchange of RPA with the recombinase RAD51. BRCA1/BARD1 binds the RAD51 nucleofilaments to 
facilitate strand-invasion to enable the completion of homologous recombination by DNA synthesis, 













































Figure 1. 8 
Domain structure and binding partners of SMARCAD1. SMARCAD1 is a SWI/SNF remodeler in 
the INO80-subfamily as characterized by the SNF2 helicase domain that is interrupted by a long insertion 
(helicase ATP-binding domain and helicase C-terminal domain). The nuclear localization signal (NLS) 
permits SMARCAD1 import into the nucleus. The region spanning from amino acids 157-294 contains 
two tandem CUE (coupling of ubiquitin to ER degradation) domains, typically a helix that binds ubiquitin. 
The CUE domains have been suggested to bind ubiquitinated histone H2A mediated by the 
BRCA1/BARD1 heterodimer. However, the ubiquitin binding affinity of the CUE domains are weak. 
Independently of ubiquitination, the first CUE domain mediates SMARCAD1 binding to its constitutive and 
stoichiometric partner KAP1. SMARCAD1 has been demonstrated to contain a conserved CDK 
phosphorylation site a threonine 71 (T71) that permits association with TOPBP1 and recruitment to 
double strand breaks (DSBs) and promote homologous recombination (HR). Phosphorylation of T906 by 
ATM and ubiquitination by RING-1 on lysine 905 (K905) have also been required for SMARCAD1 


























Figure 1. 9 
SMARCAD1 maintains heterochromatin through replication and promotes mismatch 
repair. Along with SMARCAD1’s role in promoting homologous recombination, SMARCAD1 also 
maintains heterochromatin formation through replication and facilitates mismatch repair. (A) 
Heterochromatin (silent chromatin) regions are marked by histone H3 lysine 4 tri-methylation (H3K4me3) 
which is bound by the transcriptional repressor heterochromatin protein 1 (HP1). During replication fork 
progression, newly deposited acetylated histones are introduced. SMARCAD1 in association with PCNA 
(not depicted), KAP1, the histone deacetylases HDAC1 and 2 (HDAC1/2) along with the lysine 
methyltransferases GLP and G9a (GLP/G9a) remove the acetylation and promote the mono- and di-
methylation of H3K4. KAP1 in association with the methyltransferase Suv39h1 and PCNA (not depicted) 
enables the re-establishment of H3K9me3 and HP1 binding. (B) DNA mismatches, like the one depicted 
of a guanine (G)/adenine (A) mismatch, are recognized by the sliding clamps MutSα (MSH2-MSH6) and 
to a lesser extent by MutSβ (MSH2-MSH3) (not depicted). SMARCAD1 interacts with MSH2MSH6  and 
promotes the remodeling of the local nucleosomes to enable the completion of mismatch repair through 
EXO1 degradation of the mismatch containing area and re-synthesis of the degraded segment leading to 






Figure 1. 10 
SMARCAD1 promotes long-range end resection during homologous recombination. After 
the formation of a double strand break (DSB), 53BP1 binds to H4K20me2 and H2AK15ub as indicated in 
Figure 1.4. DSBs are rapidly sensed and bound by the MRN complex (MRE11, RAD50, and NBS1). The 
MRN complex then recruits CtIP which is then CDK-phosphorylated leading to the initial end resection of 
DNA by the MRN complex and CtIP. 53BP1 blocks the progression of the nucleases EXO1 and DNA2 
preventing long-range end resection and repair by homologous recombination (HR). Recruitment of 
SMARCAD1 leads to the remodeling of the nucleosomes in the vicinity of the DSB permitting long-range 




Chapter 2: The role of SMARCAD1 in promoting fork 
degradation in BRCA1 and BRCA2-deficient cells 
This chapter was written with help from Alberto Ciccia. 
 
2.1 Introduction 
DNA replication is the process of genome duplication during cellular proliferation. 
Failure to accurately replicate the genome causes genomic instability, an enabling 
characteristic for oncogenesis [1-3]. DNA replication fidelity is often challenged by 
obstacles, such as DNA lesions, nucleotide pool depletion, and collisions with the 
transcriptional machinery, that can cause replication fork slowing or stalling, leading to 
replication stress and eventually contributing to genomic instability and mutagenesis 
[724]. Cells have evolved various replication maintenance mechanisms to protect 
replication fork integrity [51, 725]. One level of replication maintenance that has 
emerged recently is fork reversal, which stabilizes the replication fork and facilitates the 
restart of stalled forks.  
Replication fork reversal is a protective mechanism commonly occurring during 
replication stress that remodels the replication fork into a four-way, “chicken foot”-like, 
structure, thus allowing the resumption of DNA synthesis without chromosomal 
breakage [159, 726]. Several enzymes have been demonstrated to remodel stalled 
forks in vivo in response to replication stress, including the DNA helicase FBH1, the 
recombinase RAD51, and the SNF2-family remodelers SMARCAL1, ZRANB3, and 




extruded nascent DNA on the regressed arm is a prime target for nuclease-dependent 
end resection by DNA2, MRE11, and EXO1 [36, 154, 156, 159, 727]. Limited fork 
resection by the above nucleases is critical for controlled processing of the regressed 
arm. Indeed controlled resection may assist in the removal of the chicken-foot structure 
leading to the generation of a fork structure by which replication can restart, in a similar 
manner to the E.coli RecBCD heterotrimer, or facilitate HR-mediated restart of the 
regressed forks [37, 153, 159]. However, uncontrolled fork degradation can lead to 
chromosomal instability [153, 159]. In order to protect the regressed arm from extensive 
nucleolytic degradation, RAD51 nucleoprotein filaments are assembled on the 
regressed arm and stabilized by several DNA repair factors such as: BRCA1, BRCA2, 
BARD1, PALB2, ABRO1, WRNIP1, FANCA, FANCD2, BOD1L, SETD1A, and the 
RAD51 paralogs (XRCC2 and RAD51C) [155, 214-216, 218, 226-228]. Nucleosomes 
have been characterized on the reversed arm of the forks and have been suggested to 
pose a barrier to reversed fork resection [196, 228, 318]. How nucleases may 
counteract the chromatin deposited on the reversed arm of the fork to mediate resection 
is still not known.  Without fork protection, reversed forks undergo uncontrolled 
degradation, leading to genomic instability and sensitivity to chemotherapeutic agents 
[154, 215, 225, 728]. Notably, re-establishment of fork protection has been implicated in 
promoting tumor resistance to chemotherapies [154, 175, 240, 626, 627]. Therefore, 
identifying proteins associated with replication fork protection is crucial for cancer 
therapy.    
SMARCAD1 is a SNF2-family chromatin remodeler that promotes 




been shown to stimulate end-resection at DSBs to promote homologous recombination 
(HR) [680-682, 686, 709, 729]. Both DNA end-resection and heterochromatin 
maintenance functions of SMARCAD1 have been conserved from the yeast orthologs 
Fun30 (Saccharomyces cerevisiae) and Fft3 (Saccharomyces pombe) to the human 
protein [681, 709, 714, 723, 730, 731].  In particular it has been proposed that 
SMARCAD1 and its homologs enable end-resection through the mobilization or eviction 
of nucleosomes [681, 709-714, 716, 730]. Recently, both Fun30 and Fft3 have been 
characterized to contribute to cellular tolerance in response to the replication stress-
inducing agents hydroxyurea (HU) and methyl methane sulfonate (MMS). Specifically, 
Fun30 has been characterized to inhibit HR-mediated DNA damage tolerance promoted 
by the HLTF/SHPRH ortholog Rad5 [721, 722]. Strikingly, Fft3 promotes fork resection 
and HR-mediated fork restart in response to replication fork stalling [732]. However, 
while SMARCAD1 promotes HR through long-range end resection and is associated 
with the replisome, it is not known whether SMARCAD1 plays a role during replication 
stress.  
Here we report that SMARCAD1 promotes resection of nascent DNA in 
BRCA1/2-deficient mammary epithelial cells. We demonstrate that its chromatin 
remodeling domain is critical for promoting resection. Furthermore, we show that 
SMARCAD1 promotes fork restart and that loss of SMARCAD1 leads to an increase in 
DNA damage induced by replication stress agents. Finally, we demonstrate that the 
replication-induced DNA damage in SMARCAD1- and BRCA1-deficient cells is 
dependent on SMARCAL1-mediated fork reversal. Taken together, these findings 





SMARCAD1 depletion prevents nascent DNA from degradation upon fork stalling in 
BRCA1/2-deficient cells 
A recent study in the fission yeast Saccharomyces pombe has demonstrated that 
Fft3 is required for end-resection at stalled replication forks and promotes HR-mediated 
fork restart [732]. In mammalian cells, replication forks are protected from extensive 
DNA degradation by BRCA1 and BRCA2 (BRCA1/2) [214, 215]. Given that SMARCAD1 
plays a key role in promoting long range end-resection at DSBs to promote HR [681, 
682, 686, 710], we reasoned that SMARCAD1 may resect the nascent DNA of a stalled 
replication fork unprotected by BRCA1/2. To study the role of SMARCAD1 at the 
replication fork, we monitored nascent DNA degradation using the DNA fiber technique 
[306] in the non-tumorigenic human breast epithelial cell line MCF10A, subjected to 
shRNA-mediated depletion of SMARCAD1, BRCA1, and/or BRCA2. The MCF10A cells 
were pulsed sequentially with the thymidine analogs 5-chloro-2’-deoxyuridine (CldU, 
red) and iodo-2’-deoxyuridine (IdU, green), followed by treatment with 2 mM 
hydroxyurea (HU) for 5 hours to arrest DNA replication (Figures 2.1A,B). The ratio of 
IdU to CldU tract length was assessed to determine fork degradation in response to HU. 
As previously demonstrated, depletion of either BRCA1 or BRCA2 significantly reduced 
the median IdU/CldU length ratio compared to control cells in HU treatment (Figure 
2.1C). Upon co-depletion of SMARCAD1 with two independent shRNAs, this reduction 
in the IdU/CldU length ratio was eliminated (Figure 2.1C). Similarly, SMARCAD1 co-




IdU/CldU ratio by BRCA1-depletion (Figures 2.2A,B). Taken together this suggests that 
SMARCAD1 promotes the resection of the nascent DNA in BRCA1/2-deficient cells.  
The ATPase activity of SMARCAD1 is required to promote nascent DNA degradation in 
BRCA1-deficient cells 
SMARCAD1 depends on its ATPase activity to promote long-range end resection 
and drive heterochromatin maintenance during replication  [681, 686, 710, 729]. 
Additionally, it has been demonstrated that SMARCAD1 is recruited to DSBs by 
TOPBP1 through a conserved CDK phosphorylation site, threonine 71 (T71) [709]. 
Furthermore, it was shown that SMARCAD1 requires its tandem Cue domains for 
localization and function [682], and ubiquitination of lysine 905 (K905) by RING-1 [686] 
to promote end resection. To test whether SMARCAD1 requires its ATPase activity, 
TOPBP1 binding, Cue domains, or ubiquitination by RING-1 to promote resection at the 
replication fork in BRCA1-deficient cells, SMARCAD1 shRNA-depleted cells were 
complemented with shRNA resistant cDNAs encoding either the wild type (WT), 
ATPase-defective (K528R), phosphorylation-defective (T71A), Cue domain-mutant 
(CueM), or ubiquitin-defective (K905R) forms of SMARCAD1. Detection of the levels of 
the complemented SMARCAD1 proteins by western blotting revealed that only the 
T71A and K528R mutants were expressed at levels comparable to WT SMARCAD1 
(Figure 2.2C). Expression of the WT and T71A forms of SMARCAD1, but not of its 
ATPase-defective form, promoted nascent DNA degradation in BRCA1-depleted cells 
upon HU treatment (Figure 2.1D). This finding suggests that SMARCAD1 promotes 




ATPase activity. Future studies are required to determine whether SMARCAD1 
promotes MRE11-, DNA2-, or EXO1-mediated stalled fork resection. 
SMARCAD1 promotes fork restart 
To determine whether SMARCAD1 is required for fork restart similarly to its yeast 
ortholog Fft3, we monitored fork restart using the DNA fiber technique. To this end, cells 
were pulsed with CldU and subsequently treated with 2 mM HU for 2 hours followed by 
an IdU pulse (Figure 2.3A). Individual fibers were assessed for the incorporation of IdU 
after removal of HU, an indication of successful fork restart. After treatment with HU, 
depletion of SMARCAD1 alone significantly increased the percentage of stalled forks 
compared to control cells (Figure 2.3A). However, depletion of BRCA1 did not affect 
fork restart compared to control cells (Figure 2.3A), suggesting that extensive fork 
degradation does not prevent fork restart. Interestingly, co-depletion of BRCA1 and 
SMARCAD1 led to an increase in the percentage of stalled forks (Figure 2.3A), 
suggesting SMARCAD1 plays an important role in fork restart regardless of BRCA1/2 
status. Future studies are required to test whether SMARCAD1 relies upon its ATPase 
or other domains for proper fork restart. 
SMARCAD1 prevents replication stress induced DNA damage 
Blocked reversed forks are cleaved by the endonucleases MUS81 and SLX4, 
thus generating a DSB, which is repaired by HR [165, 237, 238]. To determine whether 
loss of SMARCAD1 promotes DSB formation due to failed fork restart, MCF10A cells 
expressing BRCA1 or SMARCAD1 shRNAs were treated with 100 nM of the 
topoisomerase inhibitor camptothecin (CPT) and subsequently subjected to an alkaline 




expected, BRCA1-depletion increased the mean comet tail moment after CPT 
treatment, as compared to control cells (Figures 2.3B and 2.4A). Interestingly, depletion 
of SMARCAD1 alone also increased the mean tail moment (Figure 2.3B), suggesting 
that SMARCAD1 protects cells from replication stress-induced DNA damage. 
Furthermore, depletion of either BRCA1 or SMARCAD1 led to similar mean tail moment 
to that observed upon co-depletion of both proteins (Figure 2.3B), suggesting that 
SMARCAD1 works in the same pathway as BRCA1 to prevent DSB generation.  
Taglialatela et al. previously demonstrated that SMARCAL1-mediated fork 
reversal is crucial for the DNA damage generated in BRCA1-deficient cells [154]. 
Therefore, we hypothesized that SMARCAD1-mediated DNA damage in response to 
replication stress may also be due to fork reversal. To this end, we depleted 
SMARCAL1 by siRNA and monitored DSB formation by comet assay (Figure 2.4B). As 
expected, depletion of SMARCAL1 reduced the mean tail moment in BRCA1-deficient 
cells (Figure 2.3C) [154]. Interestingly, SMARCAL1 depletion also reduced the mean 
tail moment for SMARCAD1-depleted cells and SMARCAD1/BRCA1 co-depleted cells 
(Figure 2.3C). Taken together, these data suggest that the replication stress induced in  
SMARCAD1-depleted cells is mediated by SMARCAL1.  
SMARCAD1 promotes nascent DNA degradation in BRCA1/2-deficient cells and fork 
restart upon replication stress 
In this study we characterize a novel role for SMARCAD1 in promoting the 
resection of the nascent DNA at stalled fork and facilitating efficient fork restart. In 
particular, we determine that the ATPase activity of SMARCAD1 is essential for 




promotes fork restart and prevents replication stress induced DNA damage (Figures 2.3 
A,C).  
2.4 Methods and Materials 
Cell culture 
MCF10A, U2OS and HEK293T cells were obtained from American Type Culture 
Collection (ATCC). HEK293T and U2OS cells were cultured in DMEM supplemented 
with 10% Fetalgro bovine growth serum (RMBIO). MCF10A cells were maintained in a 
1:1 mixture of DMEM and Ham’s F12 medium (Thermo Fischer Scientific), 
supplemented with 5% horse serum (Thermo Fischer Scientific), 20ng/ml human 
epidermal growth factor (Peprotech), 100ng/ml cholera toxin, 10μg/ml insulin and 
0.5μg/ml hydrocortisone (Sigma-Aldrich). Cells were grown in humidified incubators at 
37oC and 5% CO2. 
Plasmids 
pDONR223-SMARCAD1 was obtained from the orfeome (ID: 10760). 
pDONR223-SMARCAD1-T71A, pDONR223-SMARCAD1-K528R, and pDONR223-
SMARCAD1-K905R were generated using inverse PCR with the following DNA oligos 
respectively: 5’- TGTTCCAGAAgctCCAGATAATG-3’ and 5’-
CTAGAATCTTCTGTTTTTTCAG-3’, 5’- GGGCCTAGGAagaACTATTCAAG-3’ and 5’- 
ATTTCATCTGCCAAAATGC-3’,  5’- 
ATTAGATGGAcggACTCAGATTTCTGAAAGGATTC-3’ and 5’- 
CTGAGGTACCTATGCTGATG-3’. pDONR223-SMARCAD1-CueM was generated 
using a custom synthesized oligo containing the amino acid changes L168E, F169E, 




cloned into pDONR223-SMARCAD1 plasmid blunted by inverse PCR with the following 
DNA oligos: 5’- GAATCTCTAAAAGTGTTTGCAGAAG-3’ and 5’- 
TTCCTTCAAAGTCTGAAGTTTAGCA-3’.  shRNA resistant pDONR223-SMARCAD1 
and mutants were generated using inverse PCR using the oligos 5’- 
ccacacatgtttagtagtagcaccagtgaaataAGGCGTatgttCAGTAGCaagacaaaatcagcagatgagca
-3’ and 5’- tgctcatctgctgattttgtcttgctactgaacatACGCCTtatttcactggtgctactactaaacatgtgtgg-
3’ prior to Gateway LR recombination using LR Clonase II (Thermo Fisher) into the 
lentiviral expression vector pHAGE-N-FLAG-HA-DEST-CMV. The following retroviral 
vectors have been used to express shRNAs in this study: pMSCV-PM vectors 
containing control firefly luciferase shRNA (CCCGCCTGAAGTCTCTGATTAA) [193], 
BRCA1 shRNA (GGCAGGTATTAGAAATGAA), BRCA2 shRNA 
(CTCTTAGCTGTCTTAAAGA, SMARCAD1 shRNA #10 (ACGAAGAATGTTTTCCTCT), 
and SMARCAD1 shRNA#11 (CATAGAGTAGGCCAGACTA). Combinatorial stable 
shRNA-mediated knockdown of control, BRCA1/2, and/or SMARCAD1 in MCF10A and 
U2OS cells was achieved by two sequential rounds of infection and selection using 
recombinant viral particles derived from the above retroviral vectors carrying resistance 
to puromycin, blasticidin, or hygromycin. Control, BRCA1-deficient, SMARCAD1-
deficient, or BRCA1-SMARCAD1-deficient MCF10A cells were transfected with an 
siRNA targeting firefly luciferase (control siRNA, GE Dhaemacon) or SMARCAL1 
siRNA#1 (GE Dharmacon) using lipofectamine HiPerFect  (Qiagen) following the 
manufacture’s instructions and subjected to comet assays 2 days after transfection. The 
expression of the lentiviral vectors pHAGE-GFP-FLAG-HA, pHAGE-SMARCAD1, 




and pHAGE-SMARCAD1-K905R were generated by a sequential round of infection and 
selection on top of the combinatorial stable shRNA-mediate knockdowns using 
recombinant viral particles derived from the above lentiviral vectors carrying resistance 
to puromycin.  
DNA fiber analysis 
Exponentially asynchronously growing MCF10A and U2OS cells were pulse 
labelled with two thymidine analogs 25μM 5-cholor-2’-deoxyuridine (CldU, Sigma 
Aldrich) and 125μM 5-iodo-2’-deoxyuridine (IdU, Sigma Aldrich) for the indicated times. 
To measure DNA degradation, after pulse labeling with the second nucleotide analog, 
the cells were washed three times with 1X PBS and treated or not with hydroxyurea 
(HU, 2mM, Sigma-Aldrich), HU+ mirin (50μM, Sigma-Aldrich) for 5 hours. To measure 
fork stalling, after the first pulse, the cells were washed 3 times with 1X PBS and treated 
or not with 2mM HU for 2 hours, washed with 1X PBS three times, and subsequently 
labeled with the second analog. Labeled cells were trypsinized and resuspended in cold 
1X PBS at 4 x 105 cells/mL. Then 2μL of the suspension were spotted onto a pre-
cleaned glass slide and lysed with 10μL of spreading buffer (0.5% SDS in 200mM Tris-
HCl pH 7, and 50mM EDTA). After 6 minutes of incubating in a humidity chamber, the 
chamber was tilted 15-20° relative to the horizontal allowing the DNA to spread. Slides 
were air dried, fixed with an ice-cold mixture of methanol and acetic acid (3:1) for 2 
minutes, rehydrated in 1X PBS, and denatured with 2.5M HCl for 50 minutes at room 
temperature. Slides were then rinsed in 1X PBS and blocked for 1 hour in blocking 
buffer (4% BSA and 0.1% Triton X-100 in 1X PBS) for 1 hour at room temperature. Rat 




(Becton Dickinson, 347580) were diluted 1:100 each in the blocking buffer and applied 
to detect CldU and IdU respectively. After 1 hour of incubation in a humidity chamber, 
slides were washed with 1XPBS and stained with Alexa Fluor 488-labelled goat anti-
mouse IgG1 antibody (Thermo Fisher Scientific) and Alexa Fluor 594-labeled goat anti-
rat antibody (Thermo Fisher Scientific) diluted 1:300 each in blocking buffer for 30 
minutes. Slides were washed with 1X PBS, air dried, and mounted with Prolong Gold 
Antifade (Thermo Fisher Scientific) and held at 4°C. Replication tracks were imaged on 
a Nikon Eclipse 50i microscope fitted with a PL Apo 40X/0.95 numerical aperture (NA) 
objective and measured using ImageJ software. 
Comet Assay 
Double and single-stranded DNA breaks were evaluated by alkaline comet assay 
(single cell gel electrophoresis). MCF10A cells were plated 1 x105 cells/well in a 12-
multiwell plate 2 days after transfection and the following day treated or not with 
camptothecin (CPT, 100nM, Sigma Aldrich) for 5 hours before collection. Cells were 
trypsinized, re-suspended in 1X PBS, and mixed with molten LMA agarose and pipetted 
onto a CometSlide (slide coated with 1% NMA agarose in 1X PBS). The slides were 
subsequently incubated with a lysis solution at pH 10 (25mM NaCl, 100mM EDTA, 
10mM Tris Base) for 16 hours at 4°C, equilibrated in running buffer pH 13 (300mM 
NaOH, 1mM EDTA) for 20 minutes. The slides were then placed in a horizontal 
chamber (FisherBiotech) and alkaline electrophoresis was performed at 19V for 20 
minutes. Slides were then washed with a neutralization buffer (0.4M Tris-HCl, pH 7.5) 
for 15 minutes, fixed with ice-cold ethanol for 5 minutes, and stained with a fluorescent 




experimental point using a Nikon Eclipse 50i microscope. The comet tail moment values 
were determined using the CometScore Software. Apoptotic cells (small comet head 
with very large comet tails) were excluded from the analysis. 
Western Blotting 
Cells were collected by trypsinization and lysed in 2X SDS-Page buffer (62.5nM 
Tris-HCl pH6.8, 2% SDS, 25% glycerol, 0.01% bromophenol blue, 5% β-
mercaptoethanol). Following gel electrophoresis and transfer of cell extracts onto a 
nitrocellulose membrane, membranes were incubated for 1 hour with blocking buffer 
(5% milk in TBS+ 0.1% tween). Membranes were subsequently incubated for 2 hours at 
room temperature or overnight at 4°C with primary antibodies diluted in antibody buffer 
(5% BSA in TBS+ 0.1% tween) and detected using the appropriate horseradish 
peroxidase (HRP)-conjugated secondary antibody diluted 1:1000 in blocking buffer. The 
HRP signal was detected using SuperSignal Western Pico Chemiluminescent Substrate 
(Thermo Scientific) and autoradiography films (Research Products International). Anti-
SMARCAD1 (1:20,000, ThermoFisher Scientific, PA5-53482), anti-SMARCAL1 
(1:1,000, SantaCruz, sc-376377), anti-BRCA1 (1:75, SantaCruz, sc-6954), anti-BRCA2 
(1:1,000, Bethyl, A300-005A), anti-vinculin (1:100,000, Sigma-Aldrich, V9131), anti-
Tubulin (1:100,000, Abcam, ab6160) antibodies were used in western blot experiments. 
Antibodies 
The following antibodies were used in this study: Anti-SMARCAD1 
(ThermoFisher Scientific, PA5-53482), anti-SMARCAL1 (SantaCruz, sc-376377), anti-
BRCA1 (SantaCruz, sc-6954), anti-BRCA2 (Bethyl, A300-005A), anti-vinculin (Sigma-




MCA2060T), anti-Bromodeoxyuridine (Becton Dickinson, 347580), Alexa Fluor 488-
labelled goat anti-mouse IgG1 antibody (Thermo Fisher Scientific), and Alexa Fluor 594-
labeled goat anti-rat antibody (Thermo Fisher Scientific). 
Recombinant viral production and infection 
Recombinant retroviruses and lentiviruses were generated by co-transfecting 
helper packaging vectors together with retroviral or lentiviral vectors into HEK293T cells 
using the TransIT-293 transfection reagent (Mirus). Virus-containing supernatants were 
collected 48 hrs after transfection and utilized to infect MCF10A and U2OS cells in the 
presence of 8 μg/ml polybrene. 48 hours after viral addition, MCF10A and U2OS cells 
were selected using 1 μg/ml puromycin, 10 μg/ml blasticidin, or 100 μg/mL hygromycin 
for 3-5 days.  
Quantification and statistical analysis 
Statistical differences in the DNA degradation experiments were analyzed by a 
Mann-Whitney test. Statistical differences in the comet assays were analyzed by one-
way ANOVA. Statistical analysis was performed using the GraphPad Prism software. In 










Figure 2. 1 
Analysis of nascent DNA degradation in BRCA1/2-deficient cells upon SMARCAD1 
depletion. (A) Detection by western blot of BRCA1, BRCA2, and SMARCAD1 protein levels in MCF10A 
cells subjected to shRNA-depletion. Tubulin levels are shown as a loading control. (B) Schematic of 
CldU/IdU pulse-labeling followed by 5 hours of 2mM hydroxyurea (HU) treatment (top). Representative 
images of CldU and IdU labelled replication tracks in HU-treated MCF10A cells expressing the indicated 
shRNAs. The control shRNA is a shRNA against firefly luciferase (bottom). (C) Dot plot of the IdU to CldU 
track length ratios for individual replication forks for HU-treated MCF10A cells expressing the indicated 
shRNAs. The median values are indicated by the black lines. Statistical analysis was conducted by Mann-
Whitney test (n.s. not significant; ****p<0.0001). Data are representative of 3 independent experiments. 
(D) Dot plot of the IdU to CldU track length ratios for individual replication forks for HU-treated MCF10A 
cells expressing the indicated shRNAs with or without expression of wild-type (WT), K5285, T71A -mutant 
SMARCAD1 protein. The median values are indicated by the black lines. Statistical analysis was 






Figure 2. 2 
Supplement to Figure 2.1 — Analysis of nascent DNA degradation in BRCA1/2-deficient 
cells upon SMARCAD1 depletion. (A) Detection by western blot of BRCA1, BRCA2, and 
SMARCAD1 protein levels in MCF10A cells subjected to shRNA-depletion. Tubulin levels are shown as a 
loading control. (B) Dot plot of the IdU to CldU track length ratios for individual replication forks for HU-
treated U2OS cells expressing the indicated shRNAs. The median values are indicated by the black lines. 
Statistical analysis was conducted by Mann-Whitney test (n.s. not significant; ****p<0.0001). Data are 
representative of two independent experiments. (C) Detection by western blot of BRCA1and SMARCAD1 
protein levels in MCF10A cells subjected to shRNA-depletion and expressing either GFP, wild-type (WT), 










Figure 2. 3 
Analysis of replication fork stalling and DNA damage accumulation in BRCA1-deficient 
cells upon SMARCAD1 depletion. (A) Schematic of CldU pulse-labeling followed by 2 hours of 2mM 
hydroxyurea (HU) treatment and subsequent IdU-pulse labeling (top). Quantification of fork restart 




arerepresented by three independent experiments as the mean and p-values calculated by a t-test with 
Welch’s correction (n.s. not significant; *p<0.05; **p<0.01). (B) Dot plot of alkaline comet-tail moments 
detected in MCF10A cells expressing the indicated shRNAs following a 100 nM camptothecin (CPT) 
treatment for 5 hr. Data are represented as the mean ± SEM of 75 or more comet tails per indicated 
condition and p-values were calculated by one-way ANOVA (n.s. not significant; *p<0.05; **p<0.01). Data 
are representative of two independent experiments. Representative images of the alkaline comet tails are 
shown. (C) Dot plot of alkaline comet-tail moments detected in MCF10A cells expressing the indicated 
shRNAs and siRNAs following a 100 nM CPT treatment for 5 hr. Data are represented as the mean ± 
SEM of 75 or more comet tails per indicated condition and p-values were calculated by one-way ANOVA 
(n.s. not significant; *p<0.05; **p<0.01). Data are representative of two independent experiments. 







































Figure 2. 4 
Supplement to Figure 2.3 — Analysis of replication fork stalling and DNA damage 
accumulation in BRCA1-deficient cells upon SMARCAD1 depletion. (A) Dot plot of alkaline 
comet-tail moments detected in MCF10A cells expressing the indicated shRNAs with no treatment. Data 
are represented as the mean ± SEM of 75 or more comet tails per indicated condition. Data are 
representative of two independent experiments. Representative images of alkaline comet tails are shown. 
(B) Detection by western blot of BRCA1, SMARCAD1, and SMARCAL1 protein levels in MCF10A cells 







Chapter 3: Discussion 
This chapter was written with help from Alberto Ciccia. 
 
3.1 Models for the role of SMARCAD1 at stressed replication forks  
SMARCAD1 may promote resection as a fork remodeler 
SMARCAD1 is a member of the SNF2-family, which contains three known fork 
remodelers, HLTF, SMARCAL1, and ZRANB3. While no current studies have 
demonstrated a fork remodeling activity for SMARCAD1, it is still possible that 
SMARCAD1 promotes resection indirectly via remodeling of the fork (Figure 3.1A). In 
order to determine whether SMARCAD1’s role is upstream or downstream of 
SMARCAL1-mediated fork remodeling, we have examined the formation of DNA breaks 
in response to CPT. Indeed, we found that loss of SMARCAL1 mitigated DNA break 
accumulation in SMARCAD1- and/or BRCA1-deficient cells (Figure 3.1C), suggesting 
that SMARCAL1 may act upstream of SMARCAD1 and BRCA1. CPT treatment also 
generates persistent replication-associated DSBs that need to be repaired through HR 
[733, 734]. Given the role of SMARCAD1 and BRCA1 in DSB repair [682, 686, 710, 
711], we cannot exclude the possibility that the increase in DNA break accumulation in 
response to CPT observed in SMARCAD1- and/or BRCA1-deficient cells is due to 
inability to repair DSBs by HR. Interestingly, SMARCAL1 has been demonstrated in one 
study to promote non-homologous end joining (NHEJ) by stabilizing the heterodimer 
Ku70/Ku80 and DNA-PKcs at DSB ends [735]. While a decrease in NHEJ may restore 




heterodimer can lead to the repair of persistent DSBs by microhomology-mediated end 
joining (MMEJ) [738]. In agreement with the latter case, a recent study by Chen and 
colleagues has determined that 53BP1 loss does not fully rescue the viability of BRCA1 
full knockout (KO) mice due to HR deficiency and elevated MMEJ levels [739]. 
Therefore, more studies will be needed to determine if SMARCAL1 loss increases 
MMEJ or prevents the sensitivity of SMARCAD1-deficient cells to PARP inhibitors, 
ionizing radiation or camptothecin [681, 686].  
SMARCAD1 may promote resection as a chromatin reader 
SMARCAD1 also plays an important role in regulating global histone 
deacetylation to promote histone H3 lysine (K) 9 trimethylation (H3K9me3) and 
heterochromatin formation by HP1 [680]. A recent study by Higgs and colleagues, 
identified that H3K4 methylation was an important determinant for FANCD2-mediated 
nucleosome remodeling and fork protection [228]. While loss of SMARCAD1 does not 
influence the global amount of H3K4 methylation [680], it is possible that loss of H3K9 
methylation may protect replication forks (Figure 3.1C). In agreement with this 
hypothesis, CHD4, a reader of H3K9me3, has already been implicated in promoting 
nascent DNA degradation in BRCA2-deficient cells [225, 627, 740, 741]. Therefore, an 
alternative explanation to our findings may be that depletion of SMARCAD1 leads to 
global loss of H3K9me3 and prevents CHD4 recruitment and nascent DNA degradation. 
Further studies are needed to determine if SMARCAD1 loss and, specifically, loss of 
H3K9me3, prevents CHD4 recruitment to nascent DNA. 




While SMARCAD1 promotes fork degradation in BRCA1/2-deficient cells, 
SMARCAD1 function is critical for fork restart (Figure 3.1A) suggesting that fork 
protection is not linked to fork restart. As such, we propose a mechanism in which 
SMARCAD1 is required for moving nucleosomes at the reversed arm of the fork to 
mediate controlled resection (Figure 3.1B). Interestingly, 53BP1 has been shown to be 
recruited to stalled forks [742, 743] and has been shown to protect stalled forks from 
degradation [744]. This suggests that 53BP1 can prevent resection similar to its role in 
HR. In this case, loss of SMARCAD1 would facilitate the resection of nascent DNA.  
Models for SMARCAD1 fork restart 
As discussed in Chapter 1, nucleosomes may physically pose as a barrier to fork 
restart. Therefore, nucleosomes need to be cleared to permit fork restoration by 
RECQ1. Interestingly, it was previously reported that the chromatin remodeling activity 
of Fft3 is not required for fork restart in fission yeast [723]. This aspect still needs to be 
determined for SMARCAD1.  It is possible that fork restart is mediated indirectly by 
SMARCAD1’s or it’s stoichiometric binding partner KAP1’s association with chromatin 
modifiers. As mentioned in Chapter 1, KAP1 interacts with Suv39h1, but it also acts a 
scaffold for other histone modification proteins such as SETDB1 and the NuRD complex 
[745, 746]. It is possible that SMARCAD1/ KAP1 acts as a scaffold to mediate 
chromatin modifications that promote fork restart.   
Summary 
Taken together, loss of SMARCAD1 prevents nucleosome remodeling on the 
regressed arm, thereby inhibiting fork restoration and restart, thus leading to the 




degradation and the accumulation of genomic instability (Figure 3.2B). However, 
because SMARCAD1 is present, forks can restart (Figure 3.2B). However, when 
SMARCAD1 is depleted in BRCA1/2-deficient cells, both fork degradation and fork 
restart are inhibited, leading to fork collapse and DNA damage accumulation (Figure 
3.2C). Ultimately, preventing fork reversal by SMARCAL1 prevents fork degradation. It 
has yet to be determined the effect of SMARCAL1-depletion for fork restart in 
SMARCAD1-deficient cells. More studies are needed to mechanistically understand the 
role of SMARCAD1 at stalled replication forks and provide strong evidence for this 
hypothesis. 
3.2 Inhibition of SMARCAD1 as a chemotherapeutic 
As mentioned in Chapter 1, SMARCAD1 promotes breast cancer cell migration, 
metastasis, and invasion. Notably, loss of SMARCAD1 inhibited IKK-β signaling, an 
important regulator of the NF-κB pathway [747], and STAT3 phosphorylation [693, 694]. 
Both the NF-κB pathway and phospho-STAT3 has been shown to promote cellular 
proliferation and inhibit apoptosis in triple negative breast cancers by upregulating the 
transcription of its target genes [748-750]. Moreover, phospho-STAT3 drives tumor 
immune evasion [749]. Therefore, inhibiting SMARCAD1 may prevent cancer cell 
metastasis and promote anti-tumor immunity. Similarly, MMR-deficiency contributes to a 
durable anti-tumor response and increases immunotherapy efficacy [751, 752]. MMR-
deficiency can cause insertions, deletions, base substitutions, and frameshift mutations 
which increases tumor mutational burden (TMB) and the likelihood of neoantigen 
formation [753, 754]. Strikingly, Le and colleagues demonstrate a profound difference in 




observations supporting anti-PD1 therapy for patients with MMR-deficient tumors, 
regardless of cancer type [755]. Other results support the notion that an increase in 
TMB and neoantigen load may contribute to a durable anti-tumor response during ICB 
therapy. For instance, Rizvi et al. show that patients harboring somatic mutations in 
genes involved in MMR (such as MSH2) achieved durable benefit from PD1 treatment 
[756]. Therefore, because SMARCAD1 promotes MMR [685, 688], inhibition of 
SMARCAD1 will lead to MMR-deficiency and perhaps promote immunotherapy. 
Moreover, loss of SMARCAD1 increases DSB formation during replication stress. 
Therefore, inhibiting SMARCAD1 may activate cGAS-STING mediated-innate immune 
response, thus enhancing tumor immunogenicity and response of tumors to 
immunotherapies. Taken together, inhibition of SMARCAD1 may increase neoantigen 
production and promote the cGAS-STING inflammatory response while preventing 
STAT3-driven immune evasion thereby enhancing tumor immunogenicity. Ultimately, 
inhibition of SMARCAD1 may be an effective therapeutic in combination with current 
immunotherapies.   
3.3 Conclusions and future perspectives 
Our work here has examined the pathways that maintain genomic stability and, in 
particular, characterized a new role of SMARCAD1 in response to replication stress. 
Chapter 1 explored the replication maintenance pathways in response to genotoxic 
stress and the mechanisms involved in repairing a DSB. Furthermore, chapter 1 
highlighted the dual roles of homologous recombination (HR) proteins and their 
functions at protecting the reversed arm of a stalled replication fork. In chapter 2, we 




still need to be mechanistically clarified. While we clearly demonstrate that SMARCAD1 
promotes resection at the replication fork, whether this is done by chromatin, fork, or 
epigenetic remodeling is still not understood. However, our study opens a new avenue 
of investigation on the role of chromatin context during replication stress. Overall, future 
studies are needed to elucidate the contribution of SNF2-family fork remodelers to 
tumor development along with the response to chemotherapies and immune therapies. 
Ultimately, the development of small molecules able to efficiently inhibit the activity of 
specific SNF2 fork remodelers may open new avenues for cancer therapies and 











Figure 3. 1 
Models for SMARCAD1’s role at a stressed replication fork. (A) SMARCAD1 can remodel 
stressed replication forks into a reversed fork. (B) Nucleosomes are assembled on the reversed arm of 
the fork and prevents resection by nucleases. SMARCAD1 subsequently remodels the nucleosomes on 
the reversed arm of the fork to facilitate fork restoration. (C) SMARCAD1 promotes H3K9me3 deposition 
leading to CHD4 recruitment. CHD4 then facilitates the recruitment and function of nucleases on the 












Figure 3. 2 
Summary of SMARCAD1-, BRCA1-, and SMARCAD1-and BRCA1-deficient phenotypes. 
(A) SMARCAD1-deficiency during replication stress causes fork stalling and DNA damage accumulation 
but display no fork degradation. (B) BRCA1-deficiency during replication stress leads to excessive fork 
degradation resulting in DNA damage accumulation. BRCA1-deifcient cells do not have any fork restart 
defects. (C) SMARCAD1 depletion in BRCA1-deficient cells restores dork protection but leads to fork 

















Appendix I: Programmable gene editing by CRISPR-Cas9 
Chapter A1: Introduction 
This chapter was written with help from Tarun Nambiar and Alberto Ciccia. 
 
A1.1 RNA-guided genomic editing by CRISPR-Cas9 
A1.1.1 Genome engineering technologies using protein-DNA binding 
Direct manipulation of the genome is the gold standard for functional analysis. 
Three crucial advancements have enabled precise genome editing and manipulation: 
(1) an increased comprehension of DNA transcription and repair mechanisms, (2) 
innovations in genome sequencing, and (3) the development of target specific 
programmable endonucleases. While the development of more powerful sequencing 
technologies have so far generated a wealth of genomic information [757], and 
increases in computing power ultimately decreased the cost of sequencing [758], the 
increased comprehension of DNA transcription and repair mechanisms along with the 
development of programmable endonucleases catalyzed the gene editing revolution.  
Initially, the mammalian genome was altered by the insertion of exogenously 
provided sequences which was discovered to occur by homology-directed integration or 
gene targeting involving the homologous recombination (HR) repair proteins [759-762]. 
Unfortunately, gene targeting suffered from low efficiency [760-762]. A key 
breakthrough was the observation that a double strand break (DSB) could stimulate the 
homologous introduction of sequences in a site-specific manner [763-767]. These 




the genome that was recognized by a yeast endonuclease, I-SceI [763-767]. After 
integrating the I-SceI recognition sequence into the genome, introduction of the I-SceI 
meganuclease and a homologous DNA donor plasmid increased integration by several 
orders of magnitude as compared to spontaneous gene targeting or random integration 
[763-767]. However, the I-SceI endonuclease could not be modified to recognize other 
target sequences limiting its usefulness to studying DSB repair mechanisms.  
Around the same time, studies of the Flavobacterium okeanokoites restriction 
endonuclease Fok I revealed that the endonuclease can be separated into a N-terminal 
DNA binding domain and a C-terminal non-specific DNA cleavage domain [768]. The 
modular nature of the Fok I endonuclease led to the next logical step that the 
endonuclease can be fused to different DNA binding domains to direct the nuclease to a 
specific site in the genome [769, 770]. Zinc finger proteins are functionally diverse but 
contain a specific modular DNA binding motif called the zinc finger motif. Each tandem 
array of the zinc finger motif can interact with a specific triplet of nucleotides in the DNA 
suggesting that zinc finger motifs can be arranged together to recognize any DNA 
sequence [771-774]. This chimeric Fok I endonuclease fused to zinc finger motifs was 
called a Zinc Finger Nuclease (ZFN). In order to efficiently increase gene targeting 
through the generation of a DSB, two ZFNs with inversely oriented binding domains and 
no linker sequence are needed [775]. However, ZFN bioengineering is extremely 
difficult and imperfect specificity of certain ZFNs to off-target sites were found to be 
cytotoxic and mutagenic limiting its therapeutic usefulness [776, 777].  
Similar to zinc finger proteins, transcription activator-like (TAL) effector protein 




[778]. Unlike zinc finger motifs, the TAL effector protein contains individual TAL repeats 
that bind to a single base pair as determined by the repeat variable diresidue (RVD) 
code or two specific amino acid residues that interact with the DNA by specific 
interactions or by special accommodation of the base [778-780]. A TALEN is a chimeric 
endonuclease consisting of the Fok I nuclease domain fused to a series of TAL repeats 
to mediate the binding of Fok I to a target site [781-783]. Therefore, bioengineering of 
TALENs is easier than with ZFNs. Furthermore, TALENs have higher specificity and 
lower cytotoxicity than ZFNs [783]. A major limitation to both TALENs and ZFNs are 
their reliance on protein-DNA interactions. The variability in protein affinity and activity 
based from the DNA binding motifs fused to the proteins necessitates additional in vitro 
validations and the construction of multiple TALENs or ZFNs for a given genomic 
sequence limiting high-through-put screening and precision medicine applications. 
A1.1.2 Re-purposing the RNA-guided adaptive response, CRISPR/Cas, for 
genome editing 
An alternative to TALENs or ZFNs, was first discovered as an adaptive immune 
response in prokaryotes to invading pathogens called the CRISPR/Cas system. This 
adaptive immune response consists of the integration of foreign nucleic acids into the 
genome by RNA-guided endonucleases to store a record of the invasion and mount a 
response upon re-exposure [784-787]. Integration of the viral or foreign DNA into the 
genome occurs in a polar manner with the newest sequence added to the first position 
of the repetitive element called CRISPR (Clustered Regularly Interspersed Short 
Palindromic Repeat) [786, 788-790]. The CRISPR array consists of variable sequences 




sequence that is conserved for the given CRISPR array with some repeats predicted to 
generated a stable RNA hairpin [786, 788-792]. The cognate spacer sequence native to 
the foreign element is called the protospacer, Adjacent to the CRISPR locus is a 
variable cassette of genes called the CRISPR associated genes (cas) which encode 
functional Cas proteins involved with RNA processing and DNA cleavage [784, 787, 
793, 794]. In order to confer immunity, the Cas proteins incorporate the foreign DNA 
into the CRISPR locus and subsequently transcribe them as a CRISPR RNA (crRNA) 
template for targeted destruction of the protospacer at either the DNA or RNA level 
[792, 795-798]. Of these Cas proteins, Cas 1 and Cas2 are highly conserved through 
the diverse CRISPR-Cas systems [799]. The Cas1 and Cas2 proteins are responsible 
for integrating the short foreign pieces of DNA into the CRISPR locus as spacers a 
process known as spacer integration [800-802]. Due to its diversity, the classification of 
the CRISPR-Cas system into two classes is based on the organization of the CRISPR-
Cas locus, the types of cas genes, sequence similarity between the Cas proteins, the 
structure of the CRISPR array itself, and the phylogeny of Cas1 [799, 803-806]. Class I 
CRISPR-Cas systems (types I, III, and IV) employ a multi-protein effector complex 
composed of multiple Cas proteins that assemble into a complex containing different 
numbers of Cas subunits and participates from pre-crRNA processing to target 
cleavage [803, 804, 807, 808]. Class II systems (types II, V, and VI ) employ a single 
multidomain effector protein [804, 809]. The effector module of the CRISPR-Cas system 
binds to the transcribed spacer and repeat sequence, promotes complementary base 
pairing with the foreign DNA or RNA, and finally cleavage of the phosphodiester bond 




sequence adjacent to the protospacer, called the PAM (protospacer adjacent motif) [or 
protospacer flanking sequence, PFS, for type VI], that is recognized by the integration 
module in a base-specific manner [810-815]. The integrated spacer and mature crRNA 
are, therefore, complementary to the protospacer but lacks the PAM motif. PAM 
recognition, is also, a critical part of the effector targeting and is required for ATP-
dependent strand separation and crRNA-DNA heteroduplex formation for target 
interference [816]. The lack of the PAM in the host genome and requirement for effector 
cleavage prevents auto-cleavage and autoimmunity [817]. Because Class II systems 
only use a single multidomain protein, it became an attractive tool for genome editing 
applications. Notably this class is exemplified by the type II Cas9 protein that is currently 
the most widely used genome editing tool [818].  
A1.1.3 The Cas9 effector as a promising molecule for genomic engineering 
The Streptococcus pyogenes (S. pyogenes) type IIA CRISPR-Cas system 
consists of 4 Cas genes (Cas 1, Cas 2, Cas9, and Csn2), two non-coding crRNAs, a 
trans-activating crRNA (tracrRNA) and the spacer/repeat array (pre-crRNA) [819, 820]. 
Unlike other CRISPR-Cas systems, type II systems require the tracrRNA for crRNA 
maturation and crRNA-guided mobile element cleavage by Cas9 [820, 821]. 
Specifically, the entire CRISPR array is transcribed as a long continuous RNA 
transcript, pre-crRNA, which is processed by the tracrRNA in complex with RNase III 
and Csn2 to generate mature crRNAs [820, 821]. The mature crRNAs then base pairs 
with the repeat sequence of the tracrRNA enabling Cas9 interaction with the crRNA 




mature crRNA and a partial tracrRNA can be fused into a chimeric RNA called the 
single guide RNA (sgRNA) to target the Cas9 to DNA [821].  
Cas9 Activity 
Cas9 is a large bi-lobed RNA-activated protein that promotes DNA cleavage in 
an RNA-directed manner [822-824]. The N-terminal half of the protein contains a RuvC-
like domain that is part of the Nuclease (NUC) lobe and a large α-helical arginine rich 
region called the Helical Recognition (REC) lobe while the C-terminal half contains 
several RuvC-like domains and an HNH-domain contributing the rest of the NUC lobe 
as well as a PAM-interaction site (PI) [822, 823]. The RuvC active site cleaves the non-
target strand (not complementary to the crRNA sequence) while the HNH-active site 
undergoes an RNA-dependent conformational change to cleave target strand [819, 821-
827]. The Cas9-RNA complex searches DNA through three-dimensional diffusion and 
rapidly dissociates from non-PAM sites and non or partially complementary-crRNA sites 
[824, 828]. Cas9 recognizes the PAM sequence through major groove interactions 
between the protein and the DNA facilitating R-loop formation and activating both 
nuclease domains enabling target DNA cleavage [823, 828, 829]. 
Genomic engineering using Cas9 
The S. pyogenes Cas9 (SpCas9) was the first to be reconstituted in mammalian 
cells through the expression of a codon optimized Cas9 bearing a nuclear localization 
signal and the chimeric sgRNA [830-832]. Altering the spacer, seed, sequence in the 
sgRNA enables Cas9 to be re-directed to any genomic target adjacent to the 
appropriate PAM making [830]. Different Cas9 homologs recognize unique PAM 




adjacent to two guanines (NGG) while the homolog of SpCas9, SaCas9 from S.aureus, 
recognizes a sequence of any base adjacent to a guanine (G) next to two base purines 
(A/G) and a thymine (T) or NNGRRT PAM [833]. Therefore, using different homologs of 
Cas9 enables expanded genetic sequence targeting capabilities. Furthermore, unlike 
TALENs and ZFNs, several sgRNAs can be introduced to target different genomic loci 
simultaneously making it applicable to multiplex screening methodologies [830, 834-
836]. Because the Cas9 molecule relies upon RNA-DNA hybridization dynamics and 
subsequent conformational changes for accurate gene targeting, the reliability of the 
CRISPR technology has been hampered by unintended cleavage of sites with 
mismatches to the sgRNA [837-840]. As such, there are ongoing efforts to detect and 
reduce off-target cleavage sites. Strategies to detect off-target sites map Cas9 binding 
sites or Cas9 activity such as SITE-seq, DIG-seq, CIRCLE-seq, GUIDE-seq, BLISS, 
and DISCOVER-seq [839, 841-847]. On the other hand, strategies to reduce off-targets 
include truncating the sgRNA to weaken the sgRNA-DNA duplex stability at off-targets, 
generating enhanced specificity Cas9 mutants, and computational modeling to predict 
off-targets of a given sgRNA for optimized guide selection [848]. Taken together, Cas9 
is a programmable nuclease that is currently being optimized for precise genome 
targeting. 
Repair of a Cas9-induced break 
In addition to homology-directed repair and NHEJ, DSBs can be repaired by an 
alternative end joining pathway known as microhomology-mediated end-joining (MMEJ). 
MMEJ is a DSB repair pathway that occurs in M and early S-phases and shares 




DSB ends without templated DNA synthesis similarly to NHEJ but requires end 
resection, like HDR, to expose microhomologous sequences and ultimately generates 
repair products with sequences removed, deletions, between the microhomologies [849, 
850]. Cas9-induced repair products without a homologous sequence are largely 
determined by the pathway used and Cas9 cleavage pattern. As such, +1 insertions are 
largely attributed to NHEJ-mediated repair of staggered cleavage products and 
deletions are due to MMEJ-mediated repair [851, 852]. Therefore, the repair pathways 
that underlie genome editing after a Cas9-induced break will dictate the types of edited 
products generated. 
A1.2 CRISPR applications 
The recent explosion in the development of CRISPR-based technologies [795, 
818] has produced an expansive toolbox that enables more comprehensive and 
systematic assessments protein function, contribution to genome stability, and disease 
(Figure A1.1). Because the Cas9 endonuclease generates a DSB, the addition of a 
homologous sequence can mediate the precise editing of a loci through HDR. HDR can 
be used to disrupt gene expression (knockout) by the expression of a gene disruption 
cassettes (Figure A1.1). On the other hand, mutation of either the HNH or RuvC 
domain can generate a nickase Cas9 (nCas9), which only cleaves a single DNA strand, 
that can be utilized similarly to precisely edit a locus using HDR by targeting the nickase 
with dual offset sgRNAs in a manner analogous to ZFNs or TALENs or by a single 
nCas9 through non-canonical HDR independent of CtIP [821, 831, 853-855]. Paired 
nCas9 or nCas9 alone can reduce off-target activity while a paired nCas9 has similar 




domains generates a nuclease dead Cas9 (dCas9) that retains its RNA-guided DNA-
binding activity allowing site-specific genetic and epigenetic regulation, protein 
interaction, and imaging applications [857-866]. In particular, transcriptional activators, 
VP64, and repressors, the KRAB domain, can be directed to target gene promoters and 
enhancers through their fusion with dCas9, to either induce expression, CRISPR-
activation (CRISPRa), or prevent transcription, CRISPR-interference (CRISPRi) (Figure 
A1.1) [863, 867, 868].   
CRISPR-Cas9 has enabled forward genetic screening at a genome-wide scale, 
ideal for studying biological systems in an unbiased manner. Pooled CRISPR screens 
have enabled the ability to screen thousands of genes in an unbiased manner in only 
one experiment by delivering a library of sgRNAs such that a single cell receives a 
single sgRNA and measuring viability, drug survival, or marker-based selection (Figure 
A1.1) [835, 868-874]. However, pooled screens are not compatible with identifying mild 
phenotypes [868]. Unlike pooled screens, arrayed screens use sgRNAs arranged in a 
multi-well format to examine individual perturbations, but often are more labor intensive 
(Figure A1.1) [875-877]. Combinatorial screens enable research into how genes 
function together in networks. These use dual sgRNAs that are paired with either control 
sgRNAs (non-targeting/scrambled) so that the effect of the individual sgRNA can be 
compared to the double sgRNAs to map relevant interactions on viability or survival 
[878-881]. This screening method used lentiviral vectors containing the same promoter 
and repetitive elements, which are prone to recombination leading to a decrease in 
combinatorial screening efficiency [836, 878, 880]. An alternative approach that was 




with orthologous promoter sequences to decrease recombination and enable more 
robust combinatorial screening [881]. Additionally, combinatorial screens enable more 
intricate combinations including CRISPRa and CRISPRi cell expression platforms with 
the knockout system to study multifaceted interaction networks [882].  
Recent advances made in applying single-cell analyses, such as in situ 
sequencing in intact cells, to pooled CRISPR screens allow for the acquisition of richer 
content for phenotypic characterization [883]. As such, differences in transcriptional and 
chromatin state under different conditions can be identified by coupling CRISPR 
screening with single cell RNA-seq (Perturb-seq, CROP-seq, TAP-seq) and chromatin 
accessibility studies (Perturb-ATAC) (Figure A1.1) [884-887]. Importantly, the rich 
content generated by these particular transcriptomic techniques has demonstrated utility 
towards characterizing two-way and higher order genetic interactions [878, 884]. 
The use of high-throughput saturation mutagenesis screens has the potential to 
uncover novel functional domains, regulatory elements and separation-of-function 
mutations as well as classify the pathogenicity of variants that occur in the human 
population. Therefore, CRISPR-mediated HDR can be used to systematically 
interrogate protein structure-function relationships (Figure A1.1). For example, a 
saturation mutagenesis screen has already been conducted for BRCA1 using CRISPR-
mediated HDR to introduce 4000 variants into 13 coding exons [888]. This proof-of-
concept study identified hundreds of novel non-functional variants of BRCA1 and 
allowed for the potential to predict pathogenicity of variants that were previously of 
unknown significance. Taken together, CRISPR-Cas9 systems are a useful research 




therapeutic potential to correct or install mutations associated with human diseases for 
the modeling and treatment of genetic disorders. 
A1.2.1 Modulating homologous recombination for increased targeting efficiency 
Increasing the efficiency of CRISPR-mediated genomic editing is critical for its 
therapeutic potential. HDR-mediated repair of a Cas9-induced break can lead to the 
incorporation of the mutations of interest or precise edit using an exogenous DNA-
template, or donor template, making it a versatile choice for modeling or repairing 
mutations associated with human diseases [889, 890]. However, because HDR is 
restricted to S- and G2-phases of the cell cycle, efficient HDR is limited to actively 
dividing cells [891-896]. Additionally, HDR is a considerably slower process as 
compared to MMEJ and NHEJ and under most conditions NHEJ is more efficient than 
HDR [897, 898]. Therefore, even in cultured cell lines or actively dividing cells, HDR 
efficiency is modest [898]. Several approaches have been used to improve HDR-
mediated efficiency including manipulating the cell cycle, small molecules to decrease 
NHEJ or enhance HDR, and increasing donor template availability. Lin et al. showed 
that timed delivery of Cas9 into M-phase synchronized cells using the microtubule 
inhibitor, nocodazole, enhanced HDR cell editing [899]. Furthermore, fusion of the Cas9 
protein with the N-terminal half of the DNA replication inhibitor protein, geminin, led to 
the expression of the Cas9 protein in a cell-cycle dependent manner and increased 
HDR rates [900-902]. Alternatively, inhibiting NHEJ by small molecules such as the 
ligase IV inhibitor SCR7, and DNA-PKc inhibitors NU7441 and KU-0060648 enhanced 
HDR rates and increased genome editing efficiency [903-905]. Furthermore, NHEJ can 




NHEJ factor 53BP1 or fusion to Cas9 leading to improved genome editing efficiencies 
[906, 907]. Moreover, ectopic expression of RAD52 or an engineered variant of RAD18 
prevented 53BP1 binding and increased editing efficiencies [907, 908]. Alternatively, 
enhancing HDR can also increase HDR efficiencies. As such, the HDR enhancer RS-1 
stimulates RAD51 activity to improve HDR efficiency [909, 910]. Finally, increasing the 
donor template availability by tethering the homologous donor sequence to the Cas9 
increases HDR efficiencies [911, 912]. In this case, Cas9 is fused to the Porcine 
Circovirus 2 Rep protein which is an HUH endonuclease that can form a covalently 
bond with unmodified single-stranded DNA (ssDNA) [911, 912]. 
Despite progress to increase HDR efficiencies, these strategies so far have the 
potential to be disruptive to the cell by altering DNA repair kinetics or cell cycle 
progression and are therefore limited to research applications. Moreover, several of 
these approaches would not be able to enhance editing efficiency in postmitotic cells. 
One common limitation to both HDR and NHEJ approaches is the reliance on the 
generation of a DSB. DSBs are toxic DNA lesions that can cause genomic 
rearrangements, activate DNA damage checkpoints, and induce cell death [913-916]. 
Recently, large mono-allelic deletions or insertions have been identified after HDR-
mediated CRISPR editing that would be disruptive for clinical applications [917]. 
Therefore, approaches that can edit the genome without inducing a DSB or relying on 
cell cycle progression would be beneficial for therapeutic applications. 
A1.2.2 Programmable base editing 
Single nucleotide polymorphisms (SNPs) or single base changes are the most 




from a single point mutation that causes an amino acid substitution leading to 
alterations in protein folding or function called a missense mutation [918-921]. In fact, 
over half of all pathogenic SNPs are cytosine (C) or guanine (G) (C•G) to adenosine (A) 
or thymine (T) (A•T) mutations resulting from the spontaneous formation of uracil and 
thymine by hydrolytic deamination of cytosine or 5-methylcytosine [918, 922, 923]. 
Consequently, correcting pathogenic SNPs would treat a substantial fraction of genetic 
diseases. Furthermore, DSBs are toxic lesions that can lead to genomic 
rearrangements or cell death so an alternative to HDR or NHEJ-mediated genome 
editing would be beneficial [913-915, 924]. Therefore, CRISPR-dependent methods 
have been developed that can directly change DNA bases without generating a DSB 
[922, 925-932].  
CRISPR-dependent base editing consists of a dCas9 or nCas9 fused to a 
cytosine deaminase, APOBEC1 or AID, or an engineered tRNA adenine deaminase 
(TadA) called cytosine base editors (BE) or adenine base editors (ABE) (Figure A1.2) 
[922, 925-932]. Cytosine deamination converts cytosine to uracil (U) while adenine 
deamination converts adenine to inosine (I) (Figure A1.2) [933, 934]. Base excision 
repair (BER) is the repair process that typically fixes the aberrant incorporation of U into 
the genome through recognition and removal by the uracil DNA-glycosylase (UDG) 
[935]. Therefore, a more efficient BE is generated by fusing  dCas9 or nCas9 to a uracil 
DNA glycosylase inhibitor (UGI) from the bacteriophage PBS1 (Figure A1.2A) [925]. In 
contrast to BEs, I is not as easily recognized and repaired by the BER machinery so 
ABEs do not require to be fused to an inhibitor (Figure A1.2B)  [922]. The mismatch 




synthesized DNA, in particular misincorporation of U, to increase replicative fidelity 
[936]. Therefore nCas9 is optimal for base editing since mismatch repair favors the 
repair of the nicked strand, or the non-edited strand, increasing base editing efficiencies 
and the chances that the C will be edited to a T or product purity [925]. The resulting 
G:U or I:T mismatches are then converted to A:T and G:C respectively by DNA 
synthesis (Figure A1.2) [922, 925]. Therefore, the CRISPR-dependent cytosine base 
editor BE3 is a fusion of a rat APOBEC1, a UGI, and the spCas9-D10A nickase mutant 
(Figure A1.2A) [925]. ABE7.10, on the other hand, is a fusion of two evolved TadAs to 
the spCas9-D10A nickase mutant (Figure A1.2B) [922]. The BE3 was then improved for 
efficiency and product purity by lengthening the linker between nCas9 and APOBEC1 to 
32 amino acids making a new chimera called BE4 [932]. Further improvements were 
made upon ABE7.10 and BE4 by codon optimization  and ancestral sequence 
reconstruction to generate the optimal base editing tool box of AncBE4max, BE4max for 
BEs and ABEmax for ABEs [929]. Kim et al. increased the scope of the genome 
targetable by BE3 by developing new BE chimeras containing either SaCas9, an 
engineered SaCas9, or an engineered SpCas9 variant with altered PAM specificities 
[937]. This expansion in BE3 variety increased the number of C to T (G to A) pathogenic 
mutations targetable by BE from 34% to 66% [937]. Finally, Grünewald et al. 
engineered a dual ABE and BE called SPACE that is capable of generating both A to G 
and C to T transitions on the same target [938] 
Unlike HDR-mediated genomic editing, base editing does not have a cell cycle 
dependency or the need for a homologous donor. So far base editors have been 




hepatocytes of a mouse liver, and human organoids [930, 939, 940]. Furthermore, base 
editing has been used to edit the genomes of mice, plants, and human cells [930, 941-
946]. In particular, base editing has been used to treat mouse models of amyotrophic 
lateral sclerosis (AML) and duchenne muscular dystrophy (DMD) [945, 946].These base 
editors can alter any C or A within a window 13-17 bases away from the PAM meaning 
the presence of more than one C or A within the activity window can result in the 
modification of multiple bases leading to potentially undesirable base substitutions [922, 
925, 929, 932]. There have been attempts to improve the base specificity of the base 
editors but so far only BEs have modified to have a tighter activity window (from 5 to 1-2 
nucleotides) [937]. While potentially undesirable base modifications are not favorable for 
precise base editing, it does not hinder mutations that can disrupt gene expression, 









Figure A1. 1 
The CRISPR-based technology toolbox. Overview of the tools and technologies used for gene 
editing and screening. The Cas9 protein is an RNA-guided DNA endonuclease that generates double 
strand breaks using two endonuclease domains. An engineered Cas9 can be targeted to any site in the 
genome using a guide RNA (dark blue) to interrogate the genome. Additionally, the catalytic activities of 
these proteins can be modified without effecting RNA-guided DNA-targeting. As such a Cas9 protein with 
one endonuclease domain inactivated (nCas9) or both (dCas9) can be fused to different effector proteins 
to mediate different forms of DNA editing (Base editing or Prime editing) or transcriptional modulation. 
Which editing technology tool is used depends on the editing strategy. Homology-directed repair requires 
the addition of DNA donor templates. Current approaches for saturation mutagenesis employ base 
editors. Gene knockdown by transcriptional repression by CRISPRi. Alternatively, Gene knockout can be 
accomplished by inducing a stop codon by base editing (iSTOP/ CRISPR-STOP) or integration of a stop 
cassette/ indel formation leading to a nonsense mutation as mediated by Cas9 cleavage. These 
strategies can then be employed to interrogate the genome by high-throughput screening approaches (as 
a pooled screen or an arrayed screen). Recent advances in in situ sequencing of intact cells, imaging, 
and single cell sequencing has made it possible to identify and couple phenotypes to loss-of-function or 
structure-function analyses. This overview is not comprehensive and there are several CRISPR tools and 






Figure A1. 2 
Schematic of the base editors. Overview of the structure and reactions catalyzed by the base 
editors. (A) Cytosine base editors (BEs) use a catalytically dead Cas9 (dCas9) for base editors BE1 and 
BE2 or a nickase Cas9 (nCas9) for BE3 which is fused to a cytidine deaminase, APOBEC1 or AID, and 
uracil DNA glycosylase inhibitor (UGI) (BE2, BE3, and BE4). The cytodine deaminase deaminates 
cytosine (C) converting it into a uracil (U), which during DNA replication is misread by the polymerase as 
a thymine (T) and ultimately repaired as a T, leading to the transition of guanine (G) to adenine (A). (B) 
Representative schematic of the adenine base editor ABE7.10 composed of an nCas9 fused to 2 
engineered tRNA adenine deaminases (TadAs). TadA deaminates A converting it into an inosine (I), 
which during DNA replication is misread by the polymerase as a G and ultimately being repaired to a G 











Chapter A2: Inducing stop codons by CRISPR-mediated base 
editing 
Portions of this chapter have been adapted from: 
Billon P*, Bryant EE*, Joseph SA, et al. CRISPR-Mediated Base Editing Enables 
Efficient Disruption of Eukaryotic Genes through Induction of STOP Codons. Mol Cell. 
2017; 67(6): 1068-1079.e4. doi:10.1016/j.molcel.2017.08.008. 
 
A2.1 Overview 
The introduction of a stop codon prematurely into a gene ORF, or a nonsense 
mutation, can lead to the synthesis of a truncated protein with potentially deleterious 
gain-of-function or dominant negative activity and is often associated with human 
disease (11.2% of all mutations known to cause or associate with inherited human 
diseases) [947-953]. Notably, nonsense mutations are observed in the tumor 
suppressor genes of 10%-30% of hereditary cancer patients and represent 12% of 
sporadic non-silent mutations in tumor suppressors reported by the catalog of somatic 
mutations in cancer (COSMIC) [953-957]. However, strategies to model these disease-
associated nonsense mutations have been limited. 
Nonsense mediated decay (NMD) is an mRNA quality control pathway that 
eliminates abnormal mRNA transcripts containing premature stop codons to prevent 
deleterious protein products [958-960]. If both alleles of a gene contain a nonsense 




protein expression. As such, NMD has been utilized to generate efficient gene 
knockouts through the generation of indels or frameshifts mediated by NHEJ from a 
Cas9 induced break and has been utilized in several CRISPR screens to interrogate 
gene function and uncover new genes responsible for survival, proliferation, and drug 
resistance [961-963]. Therefore, the ability to efficiently disrupt gene expression without 
requiring a cytotoxic DSB could open new avenues of study in new model organisms or 
postmitotic cells. 
Here I describe an application of CRISPR-mediated base editing for gene 
disruption studies published by Pierre Billon and Eric Bryant [964]. Experiments were 
performed by Pierre Billon with help from Tarun Nambiar, and Samuel Hayward. Eric 
Bryant performed the genome-scale analysis and wrote the R packages 
(https://github.com/CicciaLab/iSTOP) and (https://github.com/CicciaLab/iSTOP-paper) 
to reproduce the figures and computational analysis done and enable iSTOP detection 
respectively. In this study, we show that the CRISPR cytosine base editor (BE3) can 
efficiently inactivate human genes through the induction of stop codons (iSTOP) by 
precisely converting four codons (CAA, CAG, CGA, and TGG) into the stop codons 
(TAG, TAA, or TGA) and demonstrate that iSTOP-mediated editing in sgRNA-
transfected cellular pools or clones can be monitored by a restriction fragment length 
polymorphism (RFLP) assay using restriction sites targeted by iSTOP. Remarkably, 
94%-99% of genes analyzed in eukaryotic genomes can be targeted by multiple 
sgRNAs for iSTOP (sgSTOPs) while 70% of targetable sites corresponding to 98% of 
human genes can be monitored by the RFLP assay. We establish that iSTOP can be 




iSTOP a valuable gene disruption tool to study gene function and model human 
disease. To facilitate the use of iSTOP I created an online database 
(http://www.ciccialab-database.com/istop) of all sgSTOPs for the five BE3 variants 
(VQR-BE3, EQR-BE3, VRER-BE3, saBE3, and saKKH-BE3) in humans and sgSTOPs 
for eight eukaryotic species 3,483,549 targetable gene coordinates expanding the 
targeting range recently described for iSTOP-based approaches [965]. 
A2.1.1 CRISPR-mediated base editing efficiently disrupts genes through iSTOP 
CRISPR-mediated base editing converts C•G base pairs to T•A [925, 937]. 
Therefore, base editors (BEs) can convert four different codons (CAA, CAG, CGA, and 
TGG) which encode for three amino acids (glutamine [Gln], arginine [Arg], and 
tryptophan [Trp]) into the TAA, TAG, and TGA stop codons. While CAA, CAG, and CGA 
can be converted to stop codons when targeted by BEs on the coding strand, TGG can 
be converted into a stop codon if targeted on the non-coding strand. Therefore, the 
conversion of a codon into a nonsense codon through base editing has been called 
iSTOP for induction of stop codons through sgRNAs that target the site for editing 
(sgSTOPs). To efficiently monitor iSTOP-mediated edting, targeting cytosines within the 
recognition sequence of restriction enzymes that if changed could render those 
restrictions sites refractory to digestion would enable detection of the edit by a RFLP 
assay. Additionally, iSTOP-mediated editing can create new restriction sites, resulting in 
the generation of new DNA fragments upon digestion.  
In order to generate human knockout cell lines, a previously described marker-
free co-selection strategy that increases editing efficiency was used in combination with 




mutated renders cells resistant to oubain treatment [966], percent editing by iSTOP 
increased by 14.8% in HEK293T cells. Moreover, screening the co-sgSTOP transfected 
clones by RFLP analysis determined that 52.6% of the 19 clones were heterozygously 
edited and 10.5% were homozygously edited establishing iSTOP as an efficient 
approach to generate human knockout cell lines and compatible with co-selection 
strategies.  
To determine if whether this approach can be generalized to disrupt genes on a 
genome-wide scale, sgSTOPs were identified for all 69,180 ORFs in the human 
reference genome GRCh38 by using CDS coordinates from the UCSC genome browser 
to identify all CAA, CAG, CGA, and TGG codons located the correct distance from the 
PAM for all validated BE3 variants [925, 937]. This analysis revealed that 62.5% of the 
CAA, CAG, CGA, and TGG codons are targetable by iSTOP in the human reference 
genome, enabling the possibility to convert 523,340 codons into stop codons. 
Furthermore, over 80% of ORFs targetable within the first 20% of their sequence, 
99.2% of ORFs targetable within the first 100 codons, and 94.7% of ORFs targetable at 
a position predicted to cause NMD [967]. To aid in selecting sgSTOPs with low off-
target sites, we performed a genome search for sequences similar to each sgSTOP and 
observed that 74% of NGG PAM-based sgSTOPs mapped uniquely in the genome 
suggesting that a majority of the NGG-based sgSTOPs will have limited to no off-
targets. To determine whether the RFLP assay can monitor the efficiency of editing 
genome-wide, we identified restriction sites of enzymes targetable by iSTOP. This 
analysis determined that over 70% of targetable sites (corresponding to 98% of human 




two most common restriction enzymes for detecting iSTOP-mediated edits. Collectively, 
this analysis demonstrates that iSTOP is a promising tool for genome-wide disruption 
studies in human cells and that RFLP analysis allows for rapid assessment of base 
editing activity. 
Nonsense mutations are frequently associated with human disease and cancer 
with nonsense mutations accounting for 4%-5% of all observed mutations in cancer. To 
determine if iSTOP can be used to model cancer-associated nonsense mutations due to 
cytidine deamination, we determined the prevalence of C to T and G to A base 
transitions observed in the COSMIC database for the four codons CAA, CAG, CGA, and 
TGG. This analysis revealed that 61% of the cancer-associated nonsense mutations 
could be reproduced using iSTOP when considering each mutation site once 
suggesting that iSTOP can be used to efficiently model cancer-associated nonsense 
mutations.  
Several eukaryotic species are used as model organisms to understand 
biological processes. To determine whether iSTOP can be used for genome-wide 
studies in other eukaryotic species, sgSTOPs were identified for all ORFs of seven 
eukaryotic model organisms ranging from yeast (S. cerevisiae) to mice (M. musculus). 
From this analysis we identified 2,490,476 codons that can be targeted in these species 
and we found that the percentage of ORFs that can be targeted by iSTOP is between 
97% and 99,7% demonstrating that is method is robust for almost any ORF from 
various model organisms. While iSTOP can target 99.7% of human genes, this meant 
that 68 genes (0.35%) could not be targeted due to unavailable CAA, CAG, CGA, and 




have eukaryotic orthologs that can be targeted by iSTOP, therefore allowing the study 
of these genes in model organisms.  
A2.1.4 The iSTOP database 
To facilitate the use of this method, I developed a database that contains 
information on the number and percentage of alternatively spliced isoforms targeted by 
each sgSTOP, a prediction of nonsense-mediated decay, counts of putative off-target 
sites for each sgSTOP and a list of restriction enzymes that can be used to monitor 
iSTOP-mediated editing for all 3,483,549 gene coordinates. An interface for convenient 
search of sgSTOPs is available on web and mobile platforms at http://www.ciccialab-
database.com/istop (Figure A2.1).This website was developed using a Bitnami stack 
with a python-based Django web framework that interfaces with the SQL databases 
generated through the analyses. The source code for this website is available at 
https://github.com/Sarah-Joseph/iStopWebsite. This website has recently been used to 
design a library of sgSTOPs [968]. 
A2.2 Discussion and perspectives 
Overall iSTOP is a promising tool for CRISPR-mediated creation of stop codons 
to facilitate gene disruption and enable the generation of knockout cell lines. 
Additionally, we describe an RFLP assay for the easy monitoring of base editing 
efficiency in cell populations or clones. Finally we provide a convenient resources for 
searching and selecting sgSTOPs including useful annotations such as off-target 




enzymes that can be used to monitor editing as well as software to design base-editing 
guides for any annotated genome and any PAM.  
A2.2.1 Advantages over DSB-mediated disruption strategies 
Given that iSTOP causes the disruption of genes and does not mediated precise 
genome editing through the creation or correction of missense gene variants, iSTOP is 
not affected by undesirable cytosine deamination in the BE3 window of activity. 
Furthermore, unlike DSB-mediated or CRISPR-mediated base editing techniques, 
iSTOP induces the exact conversion of four codons into a stop codon. This precision 
combined with the fact that there are over 3 million targetable codons in the eight 
eukaryotic species permitting up 97%-99.7% of eukaryotic genes makes iSTOP 
compatible with genome-scale analyses in multiple model organisms. Additionally, 
iSTOP does not rely on the formation of DSBs whose formation during organismal 
development is particularly deleterious thereby potentially facilitating the generation of 
knockout organisms [969]. Furthermore, iSTOP disrupts genes without relying on 
NHEJ-induced frameshift mutations or indels which create a mosaic population. In fact, 
CRISPR-mediated base edited mice have been demonstrated to lack mosaicism [970]. 
Furthermore, iSTOP does not require donor molecules necessary for HDR making 
iSTOP a simpler disruption strategy and particularly attractive for plant bioengineering in 
which the use of DNA donor templates is hampered by technical and legislative 
obstacles [971]. Therefore, recent studies have demonstrated the CRISPR-dependent 





A2.2.2 Potential iSTOP applications 
Traditional CRISPR-strategies typically interrupt gene structure to study gene 
disruption. For ORFs that contain both coding and non-coding functions, this will make 
disrupting these loci extremely difficult. For example, the gene ASCC3 encodes for long 
and short isoforms as well as a non-coding RNA that have opposite effects on 
transcription recovery after DNA damage in which the short isoform promotes 
transcription recovery dependent on its non-coding RNA rather while the long isoform 
prevents recovery [972]. iSTOP will provide a possible strategy to separate the of 
coding from non-coding functions of genes. In addition, iSTOP could be employed to 
incorporate modified or non-natural amino acids into proteins using tRNAs that 
suppress the newly introduced STOP codons [973]. Moreover, by enabling the modeling 
of nonsense mutations at a genome-wide level, iSTOP could allow genome-wide 
studies to investigate eukaryotic gene functions and facilitate the identification of 
pathogenic variants in cancer through large-scale functional studies of cancer-
associated mutations. Recent work utilizing CRISPR-mediated generation of stop 
codons (CRISPR-STOP) has indeed confirmed the promising potential of iSTOP-related 
approaches for pooled screening applications [965]. In fact, Zhu and colleagues have 
proposed using iSTOP in combination with their internal barcode (iBAR) sequences for 
CRISPR-pool disruption screens as a better choice for ensuring lower false-positives 
and false-negatives by increasing the multiplicity of infection (MOI) [835].  
Moreover, ABEs have been utilized to silence gene expression by mutating the 
start codon, a method called i-Silence [974]. It was demonstrated that i-Silence 




knockout mouse with the highest editing efficiency of 90.4% [974]. Similarly to iSTOP, i-
Silence enables genome-wide gene disruption through the substitution of the start 
codon of about 92.4% of human genes (17,804 genes) as compared to 99.7% by 
iSTOP and can model 147 human disease [974]. Additionally, a total of 16,730 genes 
can be targeted by both strategies [974]. Taken together, our work establishes CRISPR-
mediated induction of stop codons as a robust and efficient gene disruption technology 
compatible with genome-wide studies to investigate eukaryotic gene functions, aid plant 
bioengineering, and model human diseases. 
A2.2.3 Limitations to iSTOP 
Although iSTOP can mediate substitutions for 523,340 codons, iSTOP is 
predicted to have reduced editing efficiency at 24% of targetable sites due to the 
restrictive rules for designing sgSTOPs. Unlike canonical Cas9-mediated editing, which 
can be programmed to generate DSBs adjacent to any PAM sequence, sgSTOPs 
require the presence of CAA, CAG, CGA, and TGG codons and a PAM located 13–17 
bps away from the targeted base(s). Although ∼60% of all available CAA, CAG, CGA, 
and TGG codons are targetable by iSTOP, the remainder cannot currently be targeted 
due to the absence of a nearby PAM sequence. An additional limitation of iSTOP is due 
to the inability of BE3 to efficiently edit cytosines with a G on the immediate 5’ side, as 
recently shown [925]. Recently, the engineering of a new SpCas9 variant, called SpRY, 
created an RNA-guided nuclease with robust activity at NRN sites opening the door for 
nearly PAMless editing [975]. Further engineering led to the creation of SpCas9-NRRH, 
spCas9-NRCH, and SpCas9-NRTH compatible with PAMs without guanines [976].  




NRRH, SpCas9-NRCH, and SpCas9-NRTH, into base editors that recognize different 
PAM sequences will increase the number of codons targetable by iSTOP. However, it 
may still be restricted by an immediate G on the immediate 5’-side. Taken together, 
further engineering is required to enable virtually unrestricted iSTOP-mediated editing. 
Similar to other CRISPR-related technologies, the efficacy of iSTOP could be 
affected by the occurrence of off-target mutations. Notably, initial work that examined 
the specificity of the cytidine deaminase activity of BE3 using a BE3 variant lacking the 
UGI domain (BE3ΔUGI) concluded that BE3 causes fewer off-targets than Cas9 [977]. 
Additional studies on BE3-dependent off-targets led to the development of a high-fidelity 
BE3 enzyme (HF-BE3) with reduced off-target base editing activity [978]. Therefore, 
more variants are being developed to reduce these off-targets such as Sniper-BE3 
which shows 2.4-16.4 fold less off-targets than BE3 and eA3A-BE3 which restricted 
editing of cytosines to only those adjacent to thymines in the window [979, 980]. Unlike 
BEs that have DNA off-targets, ABEs do not make detectable off-targets in the genome 
[981-983].     
Unfortunately, both BEs and ABEs generate RNA off-target editing and can self-
edit their own transcripts leading to heterogeneity [931, 984, 985]. And while efforts are 
being made to engineer these base editors to prevent RNA-editing, it is imperative to 
minimize all off-targets to use base editors in clinical settings [931, 984, 985].  
A2.2.4 Prime editing: A new precision gene editing tool 
Recently the CRISPR toolbox has been expanded to include a breakthrough 
approach to editing called prime editing. Anzalone and colleagues developed a nickase 




containing the donor sequence called a prime editing guide RNA (pegRNA) [986]. The 
nCas9 is guided to the genomic sequence using the pegRNA generating a D-loop. This 
loop is then nicked by nCas9 producing a 3’-phosphate followed by primer-binding of 
the pegRNA to the PAM strand allows the reverse transcriptase to use the rest of the 
pegRNA as a template to copy the edited donor. This leads to the generation of either a 
3’ flap that contains the edited sequence or a 5’ flap that lacks the editing. The 5’ flap is 
then cleaved by the structure specific endonuclease FEN1 or the 5’ exonuclease EXO1 
and 3’ flap ligation drives the incorporation of the edited strand [987, 988]. Unlike base 
editing, prime editing does rely upon a specific base to be in a window of activity. 
Furthermore, this technique enables the incorporation of insertions up to 44 base pairs 
or deletions up to 80 base pairs as well as nucleotide substitutions. Additionally, unlike 
base editors, so far prime editing has not been demonstrated to edit off-target RNA-
molecules. Taken together, prime editing is a versatile genome editing method that can 
in principle correct up to 89% of the pathogenic human variations in ClinVar and 
increases the scope of genome editing that does not rely on the creation of a genotoxic 
DSB [986].  
A2.2.5 Perspectives 
Genetic engineering and genome editing by the CRISPR-Cas system has been 
revolutionary as a research tool and opened doors for precision medicine and new gene 
therapies. Monogenic human diseases are disorders that are linked to mutations on a 
single gene. The World Health Organization currently estimates that there are over 
10,000 monogenic human diseases and as of 2005 the “monogenic genome” consists 




progressive muscular degeneration that affects one in every 3500 live male births [991]. 
Approximately, 70% of all DMD-causing mutations are due to a single or multiexon 
deletion in the Dystrophin gene causing a frameshift resulting in a truncated protein 
[991]. Therapies that can restore the frame of Dystrophin has the potential to restore 
protein function, survival, and improve muscle function [992]. Therefore, CRISPR-Cas-
mediated editing of the loci, in particular prime editing, could prevent DMD.  
Currently, spinal muscular atrophy (SMA), a monogenic neuromuscular disease, 
is being treated by a gene therapy from Novartis, called Zolgensma, in which a viral 
vector delivers a copy of the functional SMN gene to restore SMN protein function kick 
starting clinical applications of gene therapies [993, 994]. Because gene therapies will 
cure patients from their disease, these therapies come with a high price tag, for 
example Zolgensma has a $2.1 million or an annualized cost of $425,000 a year for 5 
years. Gene therapies lead to a fast depletion of the total addressable patient 
population leading to a decline in demand over time, so companies that produce gene 
therapies need to price their treatment to take in consideration the loss of revenue 
overtime. Current pricing models take in consideration the life-time cost to the patient if 
their disorder was not prevented by the therapy making gene therapies the costliest in 
the market for a one-time treatment. But there can be a case in which a patient’s gene 
therapy is only partially effective (perhaps due to some irreversible damage 
accumulated in utero). If that is the case, there is a question of whether the patient 
should be reimbursed and, if so, how much. It is imperative for gene therapy pricing 
models to be determined in anticipation for CRISPR-mediate editing as a therapeutic. 




outcomes-based payment, outcomes-based rebate, and outcomes-based annuity, but 
these alternative models face challenges in the current healthcare system [995]. On top 
of the challenges facing pharmaceutical companies, there are several ethical 
considerations for using CRISPR methods. 
While gene editing as a cure for genetic disorders is wildly favorable, CRISPR-
mediated editing could in theory be used to make cosmetic changes or enhance natural 
ability [996]. Genome editing of the germline, in which these changes could be inherited 
for generations, is cautiously permitted, although by law United States federal funding 
cannot be used to conduct research involving human embryos [996]. Cautiously is the 
key word because current CRISPR technologies still contain a non-significant frequency 
of off-target editing, and these edits, if in the genome, can be inherited for generations 
significantly alterin g the future population. For non-clinical uses including changing 
human features, the territory becomes very murky. While editing an individual to reduce 
bad cholesterol could be beneficial so would enhancing cognitive factors or muscle 
mass. As noted above, gene therapies are currently cost prohibitive as a therapeutic. 
Therefore, non-therapeutic editing could enable a system in which only the wealthiest 
individuals can be enhanced and perhaps increasing economic inequality in the United 
States. Another risk is the return of eugenics by the editing out “undesirable” traits [996]. 
These ethical discussions, and others, need to be occurring at the world stage to ensure 
that no one misuses or weaponizes the potential of CRISPR. Already, in 2018 at the 
Second International Summit on Human Genome Editing, a researcher announced the 
genomic editing of human embryos to prevent HIV infection [997]. Since then, the call 




who developed CRISPR technologies for genome editing [998]. Hopefully, as the 
technology evolves research, ethical, and healthcare guidelines will continue to re-
examine their current frameworks to maximize the great potential benefits of CRISPR-
























Figure A2. 1 
Example of a search performed on the iSTOP website. Representative images of using the 
iSTOP website to search for SMARCAD1 sgSTOPs. (A) The iSTOP homepage with the advanced search 
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